<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">82739</article-id><article-id pub-id-type="doi">10.7554/eLife.82739</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Theoretical analysis reveals a role for RAF conformational autoinhibition in paradoxical activation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-291562"><name><surname>Mendiratta</surname><given-names>Gaurav</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5091-348X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-289711"><name><surname>Stites</surname><given-names>Edward</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3783-7336</contrib-id><email>edward.stites@yale.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xez1567</institution-id><institution>Integrative Biology Laboratory, Salk Institute for Biological Studies</institution></institution-wrap><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Department of Laboratory Medicine, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03j7sze86</institution-id><institution>Yale Cancer Center, Yale School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Jura</surname><given-names>Natalia</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Takeda Development Center America, San Diego, United States</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e82739</elocation-id><history><date date-type="received" iso-8601-date="2022-08-16"><day>16</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-10-10"><day>10</day><month>10</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2019-11-20"><day>20</day><month>11</month><year>2019</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/849489"/></event></pub-history><permissions><copyright-statement>© 2023, Mendiratta and Stites</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Mendiratta and Stites</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-82739-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-82739-figures-v2.pdf"/><abstract><p>RAF kinase inhibitors can, under certain conditions, increase RAF kinase signaling. This process, which is commonly referred to as ‘paradoxical activation’ (PA), is incompletely understood. We use mathematical and computational modeling to investigate PA and derive rigorous analytical expressions that illuminate the underlying mechanism of this complex phenomenon. We find that conformational autoinhibition modulation by a RAF inhibitor could be sufficient to create PA. We find that experimental RAF inhibitor drug dose–response data that characterize PA across different types of RAF inhibitors are best explained by a model that includes RAF inhibitor modulation of three properties: conformational autoinhibition, dimer affinity, and drug binding within the dimer (i.e., negative cooperativity). Overall, this work establishes conformational autoinhibition as a robust mechanism for RAF inhibitor-driven PA based solely on equilibrium dynamics of canonical interactions that comprise RAF signaling and inhibition.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>systems modeling</kwd><kwd>computational</kwd><kwd>systems pharmacology</kwd><kwd>protein kinase</kwd><kwd>dimerization</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>K22CA216318</award-id><principal-award-recipient><name><surname>Stites</surname><given-names>Edward</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DP2AT011327</award-id><principal-award-recipient><name><surname>Stites</surname><given-names>Edward</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005190</institution-id><institution>Melanoma Research Alliance</institution></institution-wrap></funding-source><award-id>Young Investigator Award</award-id><principal-award-recipient><name><surname>Stites</surname><given-names>Edward</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001011</institution-id><institution>Joe W. and Dorothy Dorsett Brown Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Stites</surname><given-names>Edward</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100018259</institution-id><institution>Salk Institute for Biological Studies</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Mendiratta</surname><given-names>Gaurav</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Conrad Prebys Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Stites</surname><given-names>Edward</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mathematical modeling shows how RAF inhibitors can actually activate RAF kinases by stabilizing RAF proteins in the conformation capable of dimerization.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Cancer is a disease that is characterized by a collection of shared phenotypes (<xref ref-type="bibr" rid="bib14">Hanahan and Weinberg, 2011</xref>). Among these phenotypes is self-sufficiency in the pro-growth signals that aberrantly drive the continued proliferation of the cancerous cells. These excessive pro-growth signals may result from somatic mutations within a proliferation signaling pathway, and they could also result from excessive stimulation of transmembrane receptor proteins. Such pro-growth, proliferation, signals commonly pass through RAS GTPases (KRAS, NRAS, and HRAS) and RAF kinases (BRAF, CRAF, and ARAF) to initiate the RAF/MEK/ERK mitogen-activated protein kinase (MAPK) cascade.</p><p>Pharmacological agents that counteract these pro-growth signals have proven to be therapeutically beneficial in cancer. FDA-approved agents for upstream receptor tyrosine kinases that can drive proliferation through RAS/RAF signaling have proven effective for a variety of cancers. For example, EGFR inhibitors (both small molecule and therapeutic antibodies) have established benefit in lung, colorectal, and head and neck adenocarcinomas (<xref ref-type="bibr" rid="bib4">Ciardiello and Tortora, 2008</xref>). Downstream from receptor tyrosine kinases, the RAS GTPases have only recently become targetable, although for only one specific somatic mutation (KRAS G12C) (<xref ref-type="bibr" rid="bib49">Skoulidis et al., 2021</xref>). Multiple drugs have been developed to inhibit the RAF kinases (<xref ref-type="bibr" rid="bib1">Bollag et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Nakamura et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Zhang et al., 2015</xref>), and several of these agents have proven clinically valuable for RAF mutant melanoma and colorectal cancer.</p><p>The development of a drug that successfully inhibits its target protein is not sufficient to produce an effective drug. The drug must also avoid significant effects in non-diseased cells and tissues. This can be difficult, considering that the targeted protein could also be produced in the non-cancerous cells of the treated patient. For example, it was originally hoped that RAF inhibitors would be able to block the transmission of RAS signals (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Unexpectedly, RAF inhibitors were found to amplify RAS signals within the RAF wild-type context through a process that is now commonly referred to as ‘paradoxical activation’ (PA) (<xref ref-type="bibr" rid="bib16">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Heidorn et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">Poulikakos et al., 2010</xref>). PA is also associated with the development of drug-dependent squamous cell carcinomas in a subpopulation of those treated with RAF inhibitors (<xref ref-type="bibr" rid="bib52">Su et al., 2012</xref>). Despite numerous studies, the mechanisms driving PA are still not fully understood (<xref ref-type="bibr" rid="bib24">Karoulia et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Peng et al., 2015</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Paradoxical activation (PA) of the RAS pathway and its potential mechanisms.</title><p>(<bold>A</bold>) Schematic of the RAS/RAF/MEK/ERK signaling pathway and schematic of the PA concept. Whereas a RAF inhibitor can effectively inhibit RAF signaling to MEK in RAF mutant cancers, a RAF inhibitor can increase RAF signaling to MEK in cells without a RAF mutation (RAF wt). Gray triangles indicate directions of increasing RAF inhibitor (x-axis) and increasing RAF activity (y-axis) in the schematic. (<bold>B</bold>) Mechanisms that have been proposed to contribute to PA include RAF inhibitor-driven RAF dimer potentiation (DP), negative cooperativity (NC) for drug binding in trans within a RAF dimer once one protomer has bound drug, and the regulation of RAF kinase activity through conformational autoinhibition (CA).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-fig1-v2.tif"/></fig><p>A mathematical model of biochemical processes allows one to rigorously analyze what behaviors are possible for a given set of reaction mechanisms. Modeling can lead to mechanism-driven hypotheses for further experimental testing (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>; <xref ref-type="bibr" rid="bib34">McFall et al., 2019</xref>; <xref ref-type="bibr" rid="bib47">Rukhlenko et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Stites et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Stites et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Wofsy et al., 1992</xref>). Some of these mathematical models have proven useful for understanding mechanisms of anticancer agents. For example, we recently used a mathematical model to identify the mechanism (<xref ref-type="bibr" rid="bib34">McFall et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">McFall et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">McFall and Stites, 2021</xref>) that explains why colorectal cancer patients with a KRAS G13D mutation benefit from treatment with EGFR inhibitors despite KRAS mutations more commonly causing resistance to EGFR inhibitors (<xref ref-type="bibr" rid="bib7">De Roock et al., 2010</xref>). These studies are significant because a mechanistic explanation for this high-profile problem evaded determination through traditional experimental methods for approximately a decade. Thus, mathematical models can complement experimental approaches to provide new understandings to clinically relevant biological systems.</p><p>Mechanistically, two behaviors are commonly implicated as contributing to the phenomenon of PA (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). First, some RAF inhibitors have been shown to result in an increased level of RAF dimerization (<xref ref-type="bibr" rid="bib16">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Lavoie et al., 2013</xref>). This drug-induced dimer potentiation (DP) is commonly thought of as manifesting in a higher affinity between RAF protomers when one (or both) are bound to a RAF inhibitor (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>). Second, many RAF inhibitors do not appear capable of binding to both protomers of a RAF dimer equally well (<xref ref-type="bibr" rid="bib24">Karoulia et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Peng et al., 2015</xref>). As only one protomer in a RAF dimer need be signaling competent for RAF signaling to propagate (<xref ref-type="bibr" rid="bib17">Heidorn et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Hu et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Yuan et al., 2018</xref>), such negative cooperativity (NC) is posited to result in a reduced ability to fully inhibit RAF signaling. This NC is commonly thought of as manifesting in a reduced affinity for the binding of a second RAF inhibitor relative to the affinity with which the first RAF inhibitor bound (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>). Previous theoretical studies of PA have focused on these two mechanisms (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>; <xref ref-type="bibr" rid="bib47">Rukhlenko et al., 2018</xref>).</p><p>Here, we report our mathematical analysis of RAF PA. We developed a mathematical model that describes key regulatory steps in RAF signaling. We developed the model to follow biochemical and thermodynamic principles, and we derive the behaviors that logically follow from the RAF regulatory mechanisms. Our model includes three different mechanisms that contribute to PA; two have received previous theoretical attention and one (RAF autoinhibitory conformational regulation) has not previously received a mathematical consideration. Our modeling reveals that, under certain conditions, RAF autoinhibitory conformational changes and their modulation by RAF inhibitor binding can be sufficient to drive PA. We fit our model to experimental data, and the fit model suggests links between the three types of RAF inhibitors and the three mechanisms that contribute to PA. Overall, this study suggests that all three mechanisms and their modulation by RAF inhibitor binding are necessary to explain PA.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Analytical modeling of RAF autoinhibition</title><p>The regulation of RAF kinase activation is complex with multiple regulatory steps (<xref ref-type="bibr" rid="bib20">Hu et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Lavoie and Therrien, 2015</xref>; <xref ref-type="bibr" rid="bib55">Wellbrock et al., 2004</xref>, <xref ref-type="bibr" rid="bib2">Brummer and McInnes, 2020</xref>), and several of these processes have been described to play a role in PA (<xref ref-type="bibr" rid="bib3">Cho et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">Heidorn et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Holderfield et al., 2013</xref>; <xref ref-type="bibr" rid="bib27">Kondo et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">McKay et al., 2011</xref>). Conformational changes of the RAF monomer contribute significantly to RAF kinase activation (<xref ref-type="bibr" rid="bib22">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Lavoie and Therrien, 2015</xref>; <xref ref-type="bibr" rid="bib33">Martinez Fiesco et al., 2022</xref>; <xref ref-type="bibr" rid="bib55">Wellbrock et al., 2004</xref>; <xref ref-type="bibr" rid="bib60">Zhang et al., 2021</xref>). In the ‘autoinhibited’ form, associations between its N-terminus and its kinase domain maintain RAF in an inactive form that does not dimerize (<xref ref-type="bibr" rid="bib5">Cutler et al., 1998</xref>; <xref ref-type="bibr" rid="bib30">Lavoie and Therrien, 2015</xref>). In the ‘non-autoinhibited’ form, the kinase domain is no longer occluded, and other regulatory mechanisms contribute to full RAF kinase activation, such as kinase domain conformational changes and dimerization (<xref ref-type="bibr" rid="bib30">Lavoie and Therrien, 2015</xref>; <xref ref-type="bibr" rid="bib28">Lavoie et al., 2013</xref>). Recent experimental work reports that RAF inhibitors tend to promote a net transition to the non-autoinhibited conformation that is bound to RAS-GTP (<xref ref-type="bibr" rid="bib22">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Karoulia et al., 2017</xref>). It has previously been suggested that this biasing to the non-autoinhibited state may contribute to PA (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib22">Jin et al., 2017</xref>). However, conformational autoinhibition (CA) has not previously received a theoretical analysis to evaluate whether, and how, it may contribute to PA.</p><p>We therefore developed a series of mathematical models that include CA of RAF, NC within a RAF dimer, and RAF DP. We systematically studied different subsets of the full mechanism to investigate how each contributes to PA. For each sub-model, we derived analytic equations that provide the equilibrium solution for the system. One benefit of an analytic expression is that it can be utilized to determine the generality of a result and/or to identify specific criteria required for a given behavior to occur. Conclusions from most of our models are presented in theorem-proof form in Appendix 1 and are thereby devoid of any sensitivities arising from specific parameter choices. We refer to these conclusions as arising from ‘analytical modeling.’ We complement our analysis with ‘numerical modeling’ by using specific parameter values to create representative figures that can illuminate some of the predictions for the modeled network motif.</p><p>Our first mathematical model focuses on RAF CA and RAF dimerization (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The model allows RAF to adopt two different conformations: one is autoinhibited and can neither dimerize nor bind drug, and the other is non-autoinhibited and can bind drug and/or dimerize (<xref ref-type="bibr" rid="bib28">Lavoie et al., 2013</xref>). Drug-bound RAF is assumed to only be able to transition back to an autoinhibited state only after the bound drug has dissociated. Within the model, wild-type RAF is implicitly assumed to be activated by RAS-GTP as binding to RAS-GTP is an essential step to wild-type RAF activation (<xref ref-type="bibr" rid="bib30">Lavoie and Therrien, 2015</xref>). We define active RAF as the RAF protomers that are not bound to a drug and are part of a RAF dimer.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>RAF autoinhibition is a mechanism that can produce paradoxical activation (PA).</title><p>(<bold>A</bold>) Schematic of the RAF autoinhibition and dimerization model. RAF autoinhibition and the stabilization of the non-autoinhibited, dimerization, and signaling competent form of RAF by inhibitor is our first focus as a mechanism that may create PA. (<bold>B</bold>) Representative plot demonstrating that this model is sufficient to generate PA. Plotted quantity is the number of active RAF protomers (within a dimer, not bound to drug) normalized to the maximum as a function of RAF inhibitor abundance. (<bold>C</bold>) Schematic definitions of PA fold change, PA range, <italic>K</italic><sub><italic>A</italic></sub>, and <italic>K</italic><sub><italic>dim</italic></sub>. (<bold>D</bold>) Predicted PA fold change and range presented as a function of two key parameters of the autoinhibition model (<italic>K</italic><sub><italic>A</italic></sub> and [RAF]). Panels (<bold>B</bold>) and (<bold>D</bold>) are numerical examples with specific parameter values of otherwise global, analytic results of the conformational autoinhibition (CA) model that are shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Predicted paradoxical activation (PA) fold change and PA range as functions of the RAF inhibitor and RAF dimerization dissociation constants.</title><p>(<bold>A</bold>) Predicted PA fold change (left) and PA range (right) presented as a function of two key parameters of the autoinhibition model: the dissociation constant for RAF inhibitor binding with a RAF monomer (<italic>K</italic><sub><italic>d</italic></sub>) and cellular abundance of RAF ([RAF]). (<bold>B</bold>) Predicted PA fold change (left) and PA range (right) presented as a function of two key parameters of the autoinhibition model: the dissociation constant for RAF dimerization (<italic>K</italic><sub><italic>dim</italic></sub>) and cellular abundance of RAF ([RAF]). All panels are numerical examples with specific parameter values of otherwise global, analytic results of the conformational autoinhibition (CA) model that are shown in <xref ref-type="table" rid="table1">Table 1</xref>. (<bold>C</bold>) Predicted PA fold change presented as a function of the CA equilibrium constant (<italic>K</italic><sub><italic>A</italic></sub>) and also <italic>K</italic><sub><italic>d</italic></sub> (above) or <italic>K</italic><sub><italic>dim</italic></sub> (below). (<bold>D</bold>) Predicted PA range presented as a function of the CA equilibrium constant (<italic>K</italic><sub><italic>A</italic></sub>) and also <italic>K</italic><sub><italic>d</italic></sub> (above) or <italic>K</italic><sub><italic>dim</italic></sub> (below).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Visualization of how paradoxical activation (PA) arises from conformational autoinhibition with inhibitor stabilization of the open from.</title><p>Representative plots portraying the proportion of total RAF in its different states to illuminate the signaling state changes underlying PA in this mechanism. Only a RAF protomer that is within a dimer and that is also not bound inhibitor is considered active.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-fig2-figsupp2-v2.tif"/></fig></fig-group><p>The mechanism shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref> and its conversion to a set of equations that provide the system’s equilibrium solutions is detailed in Appendix 1. We use the principle of detailed balance (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>; <xref ref-type="bibr" rid="bib57">Wofsy et al., 1992</xref>) and total protein and drug conservation equations to derive closed-form, analytic expressions for the steady-state solution for this system (<xref ref-type="table" rid="table1">Table 1</xref>, with derivations in Appendix 1). We focus on steady-state solutions because PA is a steady-state phenomenon, as is reflected in the long-term outgrowth of secondary tumors with RAS mutations from patients treated with a RAF inhibitor (<xref ref-type="bibr" rid="bib52">Su et al., 2012</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Analytic conclusions in equation form for the different DP, NC, CA, and unified mechanisms models described in our work.</title><p>Predicted expressions for active RAF at baseline (no drug), active RAF, total RAF dimers, and analytic conditions for PA to occur are shown in the rows for each of the mechanism associated models. The columns show models corresponding to the PA mechanisms of drug-modulated conformational autoinhibition (CA model), drug-induced dimerization potentiation mechanism (DP model), negative cooperativity toward second drug binding (NC model), and a model that combines all these mechanisms (unified model). The lower part of the table is a key that presents the abbreviated expressions, which allow presentation into similar functional forms for corresponding model results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Model type</th><th align="left" valign="bottom">Conformational autoinhibition (CA)</th><th align="left" valign="bottom">Dimer potentiation (DP)</th><th align="left" valign="bottom">Negative cooperativity (NC)</th><th align="left" valign="bottom">Unified model</th></tr></thead><tbody><tr><td align="left" valign="bottom">Core model assumptions</td><td align="left" valign="bottom"><list list-type="order"><list-item><p>Monomeric RAF autoinhibits</p></list-item><list-item><p>Non-autoinhibited RAF can dimerize and bind drug</p></list-item><list-item><p>RAF dimers signal downstream</p></list-item></list></td><td align="left" valign="bottom"><list list-type="order"><list-item><p>RAF can dimerize and bind drug</p></list-item><list-item><p>Drug binding reduces dissociation constant of RAF dimers.</p></list-item><list-item><p>RAF dimers signal downstream</p></list-item></list></td><td align="left" valign="bottom"><list list-type="order"><list-item><p>RAF can dimerize and bind drug</p></list-item><list-item><p>Singly bound RAF dimers resist drug binding at second site</p></list-item><list-item><p>RAF dimers signal downstream</p></list-item></list></td><td align="left" valign="bottom"><list list-type="order"><list-item><p>CA model assumptions</p></list-item><list-item><p>DP model assumptions</p></list-item><list-item><p>NC model assumptions</p></list-item></list></td></tr><tr><td align="left" valign="bottom">Baseline active RAF (relative to total)</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:msqrt><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>3</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mi>E</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:msqrt><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mn>8</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:msqrt><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mn>8</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:msqrt><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>3</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mi>E</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">Active RAF (relative to total)</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msqrt><mml:mi>E</mml:mi><mml:msup><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>c</mml:mi></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>c</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mo>−</mml:mo><mml:msqrt><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:msup><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>f</mml:mi><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>f</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:msup><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>f</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>f</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:msqrt><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:msup><mml:mi>n</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>n</mml:mi></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mi>g</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>g</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msqrt><mml:mi>E</mml:mi><mml:msup><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>u</mml:mi></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>g</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>u</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>g</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">Total RAF dimers (relative to active RAF)</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>f</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>g</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">RAF PA conditions</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula><inline-formula><mml:math id="inf14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>8</mml:mn></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>3</mml:mn><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula><break/>(** necessary and sufficient)</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>f</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><inline-formula><mml:math id="inf16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>&lt;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mn>8</mml:mn><mml:mi mathvariant="normal">f</mml:mi><mml:mo>+</mml:mo><mml:mn>4</mml:mn><mml:mi mathvariant="normal">f</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><inline-formula><mml:math id="inf17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula><break/>(* sufficient)</td><td align="left" valign="bottom">No PA possible</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>g</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mi>f</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula><break/><inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>8</mml:mn><mml:mo>×</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula><inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>4</mml:mn><mml:msup><mml:mi>f</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>8</mml:mn><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mn>3</mml:mn><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula><break/>(*sufficient)</td></tr><tr><td align="left" valign="bottom" rowspan="5">Key</td><td align="left" valign="bottom" colspan="2"><inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom" colspan="2"><inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom" colspan="2"><inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>8</mml:mn><mml:mi>f</mml:mi><mml:mo>×</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom" colspan="2"><inline-formula><mml:math id="inf25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom" colspan="2"><inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom" colspan="2"><inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mn>3</mml:mn><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom" colspan="2"><inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>g</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom" colspan="2"><inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mi>u</mml:mi><mml:mo>=</mml:mo><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>g</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom" colspan="2">*Sufficient: conditions that allow PA</td><td align="left" valign="bottom" colspan="2">**Necessary and sufficient: <italic>The only</italic> conditions that allow PA.</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Paradoxical activation is a robust outcome of conformational autoinhibition</title><p>One benefit of an analytic expression is that it can be utilized to determine the generality of a result and/or to identify specific criteria required for a given behavior to occur. Along these lines, we investigated whether and under what conditions the mechanisms in our CA base model are sufficient to create PA. We can demonstrate analytically that the presence of both CA and stabilization of the active form by RAF inhibitors is sufficient to create PA for some, but not all, parameter values (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="table" rid="table1">Table 1</xref>, Appendix 1). Additionally, our analysis yields algebraic expressions that define the conditions necessary for PA to occur by this mechanism (<xref ref-type="table" rid="table1">Table 1</xref>). One condition we find is that RAF states must favor the autoinhibited form of RAF at equilibrium and in the absence of a drug for PA to occur. In other words, PA does not always happen when CA is present. By substituting biophysical parameter values into these expressions, we can predict PA for a wide range of RAF concentration values and visualize the range of system parameters for which CA promotes PA (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In our investigations, we also analytically show that PA is not generated by simpler mechanisms such as one without the autoinhibitory conformational changes and one without dimerization (Appendix 1).</p></sec><sec id="s2-3"><title>Paradoxical activation reflects a shifting balance of signaling complexes</title><p>To communicate how PA arises from this mechanism, we describe the proportion of RAF in each of its possible states: (i) autoinhibited RAF monomer, (ii) non-autoinhibited RAF monomer that is not bound to drug, (iii) non-autoinhibited monomer that is bound to drug, (iv) RAF dimer with no drug bound, (v) RAF dimer with one of two kinase domains bound to drug, and (vi) RAF dimer with both kinase domains bound to drug. We considered the total amount of kinase activity to be the number of RAF protomers within a dimer that are not bound to drug (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>Before a drug is given, a significant fraction of RAF is autoinhibited and there are low levels of non-autoinhibited RAF and RAF dimers. As RAF inhibitor levels increase, the level of autoinhibited RAF progressively declines. Non-autoinhibited RAF distributes between drug-bound monomeric and dimeric forms while the unbound monomeric form maintains equilibrium with the autoinhibited RAF. The increased quantity of RAF dimers reflects the increased pool of RAF proteins that are non-autoinhibited and therefore capable of dimerization. This results in a drug-dependent increase in RAF dimers bound to drug in one site and thereby the increase in total RAF kinase activation that accounts for PA. The quantity of drug-bound RAF monomer and doubly drug-bound RAF dimer progressively increases to saturation as a function of the drug amount, resulting in the eventual reduction in RAF kinase activity that is associated with PA dose–responses.</p></sec><sec id="s2-4"><title>Evaluation of distinct mechanisms that promote paradoxical activation</title><p>There is evidence that NC and RAF inhibitor-driven DP also contribute to PA. Previous theoretical work on PA has focused on the contribution of DP and NC (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>; <xref ref-type="bibr" rid="bib47">Rukhlenko et al., 2018</xref>). We were curious how CA might interact with these other processes that contribute to PA. We developed a mathematical model that combined the mechanisms studied in these previous studies with our model of CA; the complete mechanism that is modeled is shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref>, and we adapt the same nomenclature for parameters (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>). Analysis of our model with CA, NC, and inhibitor-driven DP finds that these three mechanisms are mathematically distinct, in that one cannot translate or rescale variables to interchange between the mechanisms (<xref ref-type="table" rid="table1">Table 1</xref>). Further, each mechanism brings a qualitatively distinct feature to the dose–response of active RAF protomers (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>) and widely diverging capacity to potentiate the fold change in PA (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>) and the width of PA (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Because of these differences, we reasoned that a mathematical model that includes these biochemically, mathematically, and qualitatively distinct mechanisms may enable the underlying mechanisms of PA to be inferred, as in an inverse problem, through computationally fitting our model to data that characterizes the PA response of RAF inhibitors.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Estimated contribution of the three major mechanisms for promoting paradoxical activation (PA).</title><p>(<bold>A</bold>) Schematic of the modeled mechanism of conformational autoinhibition extended to include dimer potentiation (characterized by parameter ‘f’) and negative cooperativity (characterized by parameter ‘g’). (<bold>B</bold>) Plot of normalized dose–response curves for nine RAF inhibitors based on model fits to the available data (<xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>). The solid lines represent mean values over N = 259 best fits for each of the 28 parameters varied. The standard deviation is highlighted in corresponding colored highlight. (<bold>C</bold>) The parameter ‘f’ and drug dissociation constant <italic>K</italic><sub><italic>d</italic></sub> values from best-fit parameter sets of the unified model (N = 259) fit to nine RAF inhibitors are shown (best-fit <italic>K</italic><sub><italic>A</italic></sub> = 2.914 ± 0.009). The outcomes of best fits for type I, II, and I.5 inhibitors are marked in black, blue, and green, ovals respectively. Dashed line at <italic>f</italic> = 1 marks the absence of dimer potentiation mechanism. For each drug, we show all obtained best-fit parameter sets that were within 10% of best-fit metric. (<bold>D</bold>) Mean percentage error per input data for best-fit parameter sets in the unified model compared to models with one mechanism excluded and two mechanisms excluded. The panel on the right presents the parameters included in the corresponding model in light green (and those that are not in dark green). Subscript ‘i’ represents each of the nine drugs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Characterizing dimer potentiation (DP), negative cooperativity (NC), and conformational autoinhibition mechanisms of paradoxical activation (PA).</title><p>(<bold>A</bold>) Maximum fold change allowed in the different mechanisms is shown with varying RAF concentrations ([RAF]) and dimerization dissociation rate constant (<italic>K</italic><sub><italic>dim</italic></sub>). CA1 represents CA mechanism with <italic>K</italic><sub><italic>A</italic></sub> = 10 (10% of RAF is active at baseline and equilibrium) and CA2 represents CA mechanism with <italic>K</italic><sub><italic>A</italic></sub> = 100 (1% of RAF is active at baseline and equilibrium). Extremal values of parameters for DP and NC mechanisms are used to derive maximal respective PA in DP, NC, and unified models (<italic>f</italic> = 10<sup>–5</sup>, g = 100). Dashed vertical line shows a physiological estimate of RAF concentration (0.04 μM). The parameters f and g are set to 1 where the respective mechanism of DP, NC is not present. (<bold>B</bold>) NC mechanism is shown within DP + NC sub-model. NC tweaks PA by extending the PA range of drug concentrations but has no impact on maximum fold change. (<bold>C</bold>) Plot of normalized dose–response curves for nine RAF inhibitors based on the unified model with all 30 parameters varied fit to the available data (<xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>). The solid lines represent mean values and highlights represent the standard deviations. (<bold>D</bold>) Parameter regions predicted when all 30 parameters of the unified model are varied, cover the same regions as in <xref ref-type="fig" rid="fig3">Figure 3C</xref>, and distribute the different types of drugs in a similar fashion. However, the best-fit range of parameter values are much wider (on a log-10 scale) than in <xref ref-type="fig" rid="fig3">Figure 3</xref>. For each drug, we show all obtained best-fit parameter sets that were within 10% of best-fit metric. (<bold>E</bold>) With all parameters of the unified model varied, the best-fit correlations between <italic>K</italic><sub><italic>A</italic></sub> values and the RAF dimerization dissociation constant (<italic>K</italic><sub><italic>dim</italic></sub>) are shown. Direct, monotonic correlation implies choosing <italic>K</italic><sub><italic>dim</italic></sub> also specifies best-fit <italic>K</italic><sub><italic>A</italic></sub>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Best-fit dose–response curves for all models for each drug.</title><p>Normalized dose–response curves for nine RAF inhibitors based on fitting the unified model and all sub-models to the available data (<xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>). The solid lines represent mean values over best fits for each of the parameters varied. The standard deviation is highlighted in corresponding colored highlight. Unified model is shown when fit with absolute error fitting metric used to compare across different models and with the chi-square-like metric that was used to identify best-fit parameter values.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Best-fit parameter values compared across different drugs.</title><p>Box and whisker plots showing the range of parameter values from our best-fit sets (i.e., parameter sets with an error no more than 10% higher than the parameter set with the least error). Best-fit parameter values for the unified model (28 parameters varied) and all sub-models are shown. Unified model bar charts are copied on each page for reference. The ‘x’ marks represent parameters that were not varied. The axes ranges represent boundaries of the parameter fits. Within the box plots, the boxes indicate quartiles, and the whiskers specify the 95% confidence interval.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-fig3-figsupp3-v2.tif"/></fig></fig-group><p>We developed a computational process for obtaining sets of parameters that fit our model to published experimental data (<xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>). Our approach finds multiple parameter sets for the same drug that are within 10% of the error for the parameter set with the least error. These published data characterize the PA response of SK-MEL-2 cells to nine different RAF inhibitors, each at seven different concentrations of inhibitor (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We reasoned that some parameters should be specific to the individual drugs (i.e., the dissociation constant for the drug binding to RAF, and the drug-induced DP and NC parameters) and that some parameters should be the same no matter which drug was used in the experiment (i.e., the abundance of RAF, the equilibrium constant of RAF dimerization when no drug is bound, and the CA equilibrium constant). We set values for two key parameters, RAF abundance and RAF dimerization equilibrium constant, based on estimates and do not fit them. A table listing the best-fit parameters of each of the sub-models is provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Of note, we have 1 global parameter (the autoinhibition equilibrium constant) and 27 drug-specific parameters. Our 28 total parameter estimates yield a model that matches the experimental data well (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Details of our approach for identifying model parameters are provided in the ‘Materials and methods’ section, and our code is provided in the supplement. We obtain similar quality overall fits if we do not pre-specify the RAF abundance and the RAF dimerization constant and add these two parameters to the other 28 parameters and then perform the same parameter estimation procedure (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C–E</xref>). We observed that some parameters could be constrained to a narrow region through this procedure, while other parameters could vary widely and still match the same data (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplements 2</xref> and <xref ref-type="fig" rid="fig3s3">3</xref>).</p><p>Intriguingly, when we considered the collection of best-fit parameters we found the different RAF inhibitors appeared to separate in a manner reflective of their known identity as type I, I.5, and II inhibitors (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). This is notable as only the RAF inhibitor dose–response data was examined to completely characterize the drug-dependent parameters, whereas the classification of kinase inhibitors is typically made by consideration of the structure of each kinase inhibitor complex (<xref ref-type="bibr" rid="bib6">Dar and Shokat, 2011</xref>). We also plot alternative parameter estimates that are within 10% error of the considered parameter set with the least error, and this helps demonstrate the robustness of this observation. Thus, our model finds that the different mechanisms result in qualitatively distinct features and our fit parameters suggest that these differences enable RAF inhibitors to be grouped based on respective mechanisms of action.</p></sec><sec id="s2-5"><title>Conformational autoinhibition and dimer potentiation together best explain PA</title><p>We next evaluated how essential all three processes are to explain the PA data. We considered the accuracy of model fits for our full model with all three mechanisms, as well as models that only included one or two of these processes. We found that the unified model (i.e., the version that includes all three mechanisms) fits the data much better than any of these sub-models (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Only the simpler model that included both CA and DP (but not NC) could fit the data nearly as well.</p><p>With respect to NC, the addition of this process to the model did add an incrementally better fit. However, the data did not strongly constrain the value of ‘g’ that defines the extent of NC (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplements 2</xref> and <xref ref-type="fig" rid="fig3s3">3</xref>). Additional experiments with a larger number of drug dose concentrations may in the future allow a better characterization of NC.</p><p>Altogether, we believe that our analysis provides strong support for CA being a critical factor to PA. Our sub-model analysis suggests that both CA and DP are necessary for the mathematical model to reproduce the experimental data with the smallest degree of error. Even though the NC term ‘g’ was not strongly constrained, and even though it had the smallest impact on the ability of the model to fit the experimental data, the model fits consistently had values of g that were much larger than 1 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), which is consistent with NC. Thus, our analysis suggests that all three processes contribute to the overall PA phenomenon.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>From our studies, we conclude that CA, NC, and drug-induced increases in dimer affinity are required to explain the PA observed with the three major types of RAF inhibitors. Our mathematical analysis suggests that the inhibitor-modulated conformational regulation of RAF kinase activity combined with conformation-dependent dimerization is a critical mechanism that drives PA. Although inhibitor-modulated CA has been recognized as a possible contributor to the entire PA phenomenon (<xref ref-type="bibr" rid="bib17">Heidorn et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Jin et al., 2017</xref>), it has been underappreciated as a mechanism capable of driving PA. Supporting this assertion is that CA has neither been discussed as a motivation for the development of third-generation RAF inhibitors (<xref ref-type="bibr" rid="bib40">Nakamura et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Zhang et al., 2015</xref>) nor has it been included in recent mathematical analyses of PA and of RAF signaling (<xref ref-type="bibr" rid="bib8">Fröhlich et al., 2022</xref>; <xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>; <xref ref-type="bibr" rid="bib47">Rukhlenko et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Varga et al., 2017</xref>). This is notable as both drug development and mathematical analyses pay considerable attention to conformations within the kinase domain (i.e., whether the alpha-C helix and DFG motif are in the ‘in’ or ‘out’ conformations) (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>; <xref ref-type="bibr" rid="bib40">Nakamura et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Rukhlenko et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Zhang et al., 2015</xref>). That suggests that the concept of structural and conformational factors on PA is not foreign to drug developers and theoretical biologists, but that they may have limited their attention to the small changes in the kinase domain that have dominated the recent literature at the expense of also considering the large, autoinhibitory, conformational changes.</p><p>Additional processes have been claimed to also play a role in PA. For example, RAF protein phosphorylation changes (<xref ref-type="bibr" rid="bib19">Holderfield et al., 2013</xref>), preferential binding of RAF inhibitor to the different RAF proteins and/or mutant RAF (<xref ref-type="bibr" rid="bib1">Bollag et al., 2010</xref>), scaffold proteins (<xref ref-type="bibr" rid="bib37">McKay et al., 2011</xref>), allosteric trans-activation (<xref ref-type="bibr" rid="bib20">Hu et al., 2013</xref>), and RAS nanoclusters (<xref ref-type="bibr" rid="bib3">Cho et al., 2012</xref>) may all further tune the response to inhibitor, including in drug-specific manners. 14-3-3 proteins can stabilize both RAF dimers (<xref ref-type="bibr" rid="bib27">Kondo et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Park et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Wilker and Yaffe, 2004</xref>) and RAF CA (<xref ref-type="bibr" rid="bib43">Park et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Wilker and Yaffe, 2004</xref>), and it has been hypothesized that 14-3-3 stabilization of dimers plays roles in PA (<xref ref-type="bibr" rid="bib27">Kondo et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Park et al., 2019</xref>). Intuitively, stabilization of RAF CA by itself would result in a stronger PA and could be approximated as an increase in the <italic>K</italic><sub><italic>A</italic></sub> term within our model. RAF stabilization of RAF dimers could be approximated as in increase in the <italic>K</italic><sub><italic>dim</italic></sub> term within our model. Although any of these other processes could potentially modulate PA, we find that our mathematical model that includes CA, NC, and drug-induced increases in dimer affinity fits the experimental data well and that those fits reproduce orthogonal biochemical features of these inhibitors. Thus, we conclude that CA, NC, and drug-induced increases in dimer affinity are the three principal mechanisms underlying PA, and that the other processes listed above may provide additional modulation of the overall behavior.</p><p>It has previously been difficult to reconcile PA for type I.5 inhibitors, which are sometimes thought of as dimer breakers because they position the alpha-C helix in the ‘out’ position (in contrast to type I and II inhibitors). Studies with recombinant protein and analytic ultracentrifugation clearly found type I.5 inhibitors to predominantly be in the monomeric form (<xref ref-type="bibr" rid="bib28">Lavoie et al., 2013</xref>). Within-cell assays have similarly found type I.5 inhibitors to promote dimerization less than other type I and II RAF inhibitors (<xref ref-type="bibr" rid="bib16">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib53">Thevakumaran et al., 2015</xref>); however, RAF inhibitors still appeared to promote some dimerization in those in-cell assays. 14-3-3 binding proteins, which can help stabilize RAF dimers, may help explain this discrepancy (<xref ref-type="bibr" rid="bib27">Kondo et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Liau et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Park et al., 2019</xref>). For example, by promoting the non-autoinhibited form, a type I.5 inhibitor-bound RAF monomer is more dimerization capable than an autoinhibited (and non-inhibitor-bound) RAF monomer. Even if the dimerization affinity is reduced compared to a non-autoinhibited and non-inhibitor-bound RAF monomer, 14-3-3 proteins may be able to bind and overcome the decrease in dimerization affinity. As our model does not explicitly include 14-3-3 proteins, this effect may contribute to our parameter estimation process finding an elevated binding affinity for type I.5-bound RAF monomers.</p><p>Although NC has been difficult to precisely measure experimentally, it has widely been assumed to be present to help explain the paradoxical activation caused by type I.5 inhibitors that do not promote dimerization as strongly as other RAF inhibitors. Our best-fit parameters did tend to have g values that were larger than 1, indicating that the model fit best when there was some NC. This could suggest that NC is more abundant than widely believed. Alternatively, the model without NC was able to fit the data nearly as well as the full model that included NC (i.e., <xref ref-type="fig" rid="fig3">Figure 3D</xref>). This may suggest that other processes not included in the model may be modulating paradoxical activation and the g parameter, as the only other term in the model, is contributing to the model’s ability to account for these otherwise not included effects.</p><p>We found parameter sets that reproduced available, published, data in order to test our model and investigate the potential for it to help illuminate aspects of PA. The best-fit parameter sets further support a role for CA and its modulation by RAF inhibitors in PA. However, it is also important not to read too deeply into the fits. For example, the data for the type II inhibitors AZ-628, LY3009120, and TAK-632 had small total fold change PA magnitudes, and our fits for them have even less PA. We anticipate that the model-fitting approach would converge to increasingly accurate estimates for the parameters as the set of data being fit to expands. Additionally, quantitative experimental measurements of the parameters being fit should also cascade to impact other parameters and result in better estimates (<xref ref-type="bibr" rid="bib13">Gutenkunst et al., 2007</xref>).</p><p>Experimental testing of model predictions is an important next step. One possible approach for experimentally investigating the role of CA on PA would involve RAF proteins that are defective in CA. Of note, there are some RAF mutants in Noonan syndrome that are believed to be activating due to impaired regulation of CA. For example, stabilization of the autoinhibited form of CRAF involves the phosphorylation of serine at residue 259 followed by 14-3-3 binding to the phosphorylated serine. The S257L, S259F, P261A, and N262K CRAF mutations are impaired at binding to 14-3-3 and have severely impaired phosphorylation of serine 259 (<xref ref-type="bibr" rid="bib26">Kobayashi et al., 2010</xref>; <xref ref-type="bibr" rid="bib42">Pandit et al., 2007</xref>). Alternatively, mutants involving the autoinhibitory domain could be used (<xref ref-type="bibr" rid="bib15">Hartsough et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Poulikakos et al., 2011</xref>). In such experiments, comparisons of RAF inhibitor dose–responses between cells expressing one such mutant against control cells expressing the wild-type equivalent RAF protein would reveal whether there were changes in PA fold change and PA range (as defined in <xref ref-type="fig" rid="fig2">Figure 2</xref>). We would expect to see reduced PA fold change and reduced PA range for the CA-impaired mutants. We anticipate that PA range would be the more useful observable because nonlinearities in downstream signaling (including possible saturation of readouts like ERK phosphorylation) may make measurements of fold change less useful. As PA range is determined by when the signal passes back through the baseline level after the increase induced by a RAF inhibitor, it should be less impacted by nonlinear signal processing downstream from RAF. Whether the experiment utilizes Noonan syndrome RAF1 mutants or truncated RAF mutants, the presence of endogenous, wild-type BRAF, ARAF, and CRAF may make it difficult to observe differences in PA due to an introduced mutant, so such experiments may need to be performed in cells where the three endogenous RAF genes are knocked out or silenced.</p><p>Our analysis was motivated by RAF inhibitors and PA in RAS mutant cells treated with a RAF inhibitor. Our model, however, is generalizable to other systems that share the modeled features. We anticipate that PA will be observed for other proteins (i) that have a dynamic-equilibrium of conformations, (ii) where not all conformations can dimerize, and (iii) where drug binding the protein stabilizes one or more of the conformations that can dimerize. As dimerization and CA are both common features for kinase regulation (<xref ref-type="bibr" rid="bib21">Huse and Kuriyan, 2002</xref>; <xref ref-type="bibr" rid="bib29">Lavoie et al., 2014</xref>), it seems reasonable to hypothesize that PA will be observed for more kinases through modulation of the conformation and dimerization dynamic equilibrium.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mathematical models and analysis</title><p>We focus on steady-state levels of the different states in which RAF can exist, as portrayed in the diagrams for each model. Between any two states, an equilibrium relationship can be expressed as the ratio of abundances in the two states. Conservation of total protein quantities and zero value of total Gibbs free energy change at equilibrium both provide mechanisms to algebraically combine these expressions. We thereby derive expressions that relate the relative abundance of the RAF within its different monomeric and dimeric states. We perform algebraic manipulations and derive analytic solutions which we cross-check using Mathematica software v 12.0 (Wolfram Research). We perform numerical evaluations of these relationships and generate plots of these equations using Python packages, including numpy, scipy, and matplotlib.</p><p>Where applicable, parameters not varied in descriptive numerical plots are set as follows.</p><p><italic>K</italic><sub><italic>A</italic></sub> = 10.0, <italic>K</italic><sub><italic>d</italic></sub> = 0.1 μM, <italic>K</italic><sub><italic>dim</italic></sub> = 0.1 μM, [RAF] = 0.04 μM. We utilize mathematical models to clarify specific mechanisms that contribute to RAF activation and drug response. The models were driven by specific hypotheses that cannot be generalized to include all the features of RAF activation simultaneously due to limitations of available experimental data that does not cover all the required conditions and variations thereof. Moreover, our analytic approach allows a parameter-independent prediction for components of canonical RAF activation cycle that would not be accessible if we attempted to include every potential feature independent of a focused hypothesis. This is similar to differences in complexity between in vitro and in vivo systems – the former often forms a more versatile and precise method of establishing mechanisms while not including most of the complexities present in vivo, thereby providing a precise testing ground for focused hypotheses.</p></sec><sec id="s4-2"><title>Model fitting to dose–response data</title><p>We reasoned that some parameters (such as the abundance of the RAF kinases, their dimerization rate constant [<italic>K</italic><sub><italic>dim</italic></sub>], and the equilibrium constant for RAF conformational changes [<italic>K</italic><sub>A</sub>]) are intrinsic to a cell and should not vary between different RAF inhibitors. The values of RAF concentrations and dimerization constant are also effective parameters since all three types of RAF are implicitly included when we fit to in vitro data. In contrast, some properties will vary between RAF inhibitors. Specifically, these would be the affinity of a drug for binding to RAF (<italic>K</italic><sub><italic>d</italic></sub>), the drug-induced change in RAF dimer affinity, or “f” to use the nomenclature of <xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>, and NC, or “g” to again use the nomenclature of <xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>.</p><p>Numerical fitting for unified model of PA mechanisms was performed using SLSQP algorithm from scipy library in Python language. Sixty-three experimental dose–response points from the PDF publication (<xref ref-type="bibr" rid="bib23">Karoulia et al., 2016</xref>) were quantified using LI-COR software (Image Studio V5.2) and used as raw data to fit 28 (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) or all 30 parameters (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C–E</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) in our model for the nine drugs included. A total of 1500 random initial states were chosen from a log-uniform search domain for each of the parameters. The boundaries of the fitting search were identified in the units of μM (where applicable) as follows: ‘f,’ [10<sup>–5</sup>,100]; ‘g,’ [1,10<sup>4</sup>]; ‘<italic>K</italic><sub><italic>A</italic></sub>,’ [0.001,10<sup>2</sup>]; ‘<italic>K</italic><sub><italic>d</italic></sub>,’ [10<sup>–4</sup>,10<sup>4</sup>]; ‘<italic>K</italic><sub><italic>dim</italic></sub>,’ [10<sup>–4</sup>,10<sup>4</sup>]; ‘RAF,’ [10<sup>–4</sup>,10<sup>3</sup>]. Best fits were defined as within 10% of the lowest value of the fitting metric. Several fitting algorithms and metrics were evaluated to finally identify SLSQP with a chi-square-like fit metric leading to convergence with higher likelihood across different initial conditions. This metric identified deviation across all data points relative to the model prediction as follows:<disp-formula id="equ1"><mml:math id="m1"><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mi>s</mml:mi><mml:mi>*</mml:mi><mml:mi>N</mml:mi><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mfrac><mml:msqrt><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msubsup><mml:mi> </mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:msqrt></mml:math></disp-formula></p><p>To compare how well each of the sub-models fit the data relative to one another, we optimized over the absolute error relative to the data as this metric has a straightforward interpretation of average proportionate deviation.<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>N</mml:mi><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mi>s</mml:mi><mml:mo>∗</mml:mo><mml:mi>N</mml:mi><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mfrac><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:munderover><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msubsup><mml:mtext> </mml:mtext></mml:mrow><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msubsup></mml:mfrac><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>In 30 parameter fits that varied all the parameters in our models, the value for RAF concentration was best fit to be 0.033 ± 0.005 μM for SKMEL2 cells (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In these fits, we also found that the dimerization equilibrium constant of RAF is monotonically correlated to autoinhibition constant <italic>K</italic><sub><italic>A</italic></sub> creating a non-identifiability problem (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Hence, other than <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C–E</xref>, the model fits were performed with a representative choice of RAF concentration fixed at 0.04 μM and RAF intrinsic equilibrium dimerization dissociation rate fixed at 0.1 μM. These parameters vary with cellular context, and the chosen values are within the range of values observed in the literature (<xref ref-type="bibr" rid="bib9">Fujioka et al., 2006</xref>; <xref ref-type="bibr" rid="bib28">Lavoie et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Sadaie et al., 2014</xref>).</p><p>Mathematica and Python files that allow for the reproduction of both our analytic and numerical analyses respectively are provided as supplementary data files and are made public on GitHub link (<ext-link ext-link-type="uri" xlink:href="https://github.com/GMendiratta/RAF-PA">https://github.com/GMendiratta/RAF-PA</ext-link> copy archived at <xref ref-type="bibr" rid="bib38">Mendiratta, 2023</xref>).</p></sec><sec id="s4-3"><title>Code availability</title><p>All codes needed to reproduce the work presented in the article are presented in the supplementary code. The codes are also available on GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/GMendiratta/RAF-PA">https://github.com/GMendiratta/RAF-PA</ext-link>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-82739-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Zipped folder containing supplementary code that enables all results to be reproduced.</title><p>Contents include a folder that includes Mathematica notebooks that derive the analytic results. Contents also include a folder that includes Python notebooks that reproduce all of the numerical results.</p></caption><media xlink:href="elife-82739-code1-v2.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Table of best-fit estimates for mechanistic parameters within the unified mechanisms model and all sub-models.</title><p>From top to bottom: best-fit parameters are shown for the DP + NC (blue), CA + NC (orange), CA + DP (green), CA (red), DP (violet), NC (brown), CA + NC + DP unified mechanisms model when 28 (black) or all 30 (gray) parameters are varied. Each of the models are fit to 63 input data points obtained from Figure 4E of <xref ref-type="bibr" rid="bib4">Ciardiello and Tortora, 2008</xref>. Input pMEK data was normalized to total MEK and then for each of the nine drugs normalized to the respective drug-free (DMSO) condition to enable comparison with model predictions. Six parameters (<italic>f, g</italic>, <italic>K</italic><sub><italic>d</italic></sub><italic>, K</italic><sub><italic>A</italic></sub>, <italic>K</italic><sub><italic>dim</italic></sub>, [RAF]) identify dose–response curve generated by each drug. Of these, three parameters (<italic>f, g, K</italic><sub><italic>d</italic></sub>) are specific to each drug, totaling to 27 parameters for the nine drugs measured. Three parameters are cell-context specific (<italic>K</italic><sub><italic>A</italic></sub><italic>, K</italic><sub><italic>dim</italic></sub>, [RAF]). For all parameter sets other than unified model 30 parameters varied, [RAF] was set to 0.04 μM and <italic>K</italic><sub><italic>dim</italic></sub> was set to 0.1 μM. All numbers shown as mean ± SD. Numerical simulations of the unified model are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></caption><media xlink:href="elife-82739-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data needed to evaluate the conclusions in the paper are present in the paper or the Supplementary Materials. All materials are available upon request from the corresponding author.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Tony Hunter, Geoff Wahl, Reuben Shaw, Bjorn Lillemeier, Dmitry Lyumkis, Joe Noel, Andrey Shaw, Rajasree Kalagiri, Leo Li, Michael Trogdon, Noah DeTal, Peter Carlip, and Melinda Tong for helpful conversations and feedback. We thank Amy Cao for help with illustrative graphics. This work was supported by a Salk Pioneer Fund Postdoctoral Scholar Award (GM); the National Institutes of Health NIH K22CA216318 (ECS), NIH DP2AT011327 (ECS), a Melanoma Research Alliance Young Investigator Award (ECS), the Joe W and Dorothy Dorsett Brown Foundation (ECS), and the Conrad Prebys Foundation (ECS).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Hirth</surname><given-names>P</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ibrahim</surname><given-names>PN</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Spevak</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Habets</surname><given-names>G</given-names></name><name><surname>Burton</surname><given-names>EA</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Tsang</surname><given-names>G</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Powell</surname><given-names>B</given-names></name><name><surname>Shellooe</surname><given-names>R</given-names></name><name><surname>Marimuthu</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>KYJ</given-names></name><name><surname>Artis</surname><given-names>DR</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Higgins</surname><given-names>B</given-names></name><name><surname>Iyer</surname><given-names>R</given-names></name><name><surname>D’Andrea</surname><given-names>K</given-names></name><name><surname>Koehler</surname><given-names>A</given-names></name><name><surname>Stumm</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>PS</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Grippo</surname><given-names>J</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</article-title><source>Nature</source><volume>467</volume><fpage>596</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/nature09454</pub-id><pub-id pub-id-type="pmid">20823850</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummer</surname><given-names>T</given-names></name><name><surname>McInnes</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RAF kinase dimerization: implications for drug discovery and clinical outcomes</article-title><source>Oncogene</source><volume>39</volume><fpage>4155</fpage><lpage>4169</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-1263-y</pub-id><pub-id pub-id-type="pmid">32269299</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>K</given-names></name><name><surname>Kasai</surname><given-names>RS</given-names></name><name><surname>Park</surname><given-names>J-H</given-names></name><name><surname>Chigurupati</surname><given-names>S</given-names></name><name><surname>Heidorn</surname><given-names>SJ</given-names></name><name><surname>van der Hoeven</surname><given-names>D</given-names></name><name><surname>Plowman</surname><given-names>SJ</given-names></name><name><surname>Kusumi</surname><given-names>A</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Hancock</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Raf inhibitors target ras spatiotemporal dynamics</article-title><source>Current Biology</source><volume>22</volume><fpage>945</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2012.03.067</pub-id><pub-id pub-id-type="pmid">22560614</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciardiello</surname><given-names>F</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>EGFR antagonists in cancer treatment</article-title><source>The New England Journal of Medicine</source><volume>358</volume><fpage>1160</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0707704</pub-id><pub-id pub-id-type="pmid">18337605</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutler</surname><given-names>RE</given-names></name><name><surname>Stephens</surname><given-names>RM</given-names></name><name><surname>Saracino</surname><given-names>MR</given-names></name><name><surname>Morrison</surname><given-names>DK</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Autoregulation of the Raf-1 serine/threonine kinase</article-title><source>PNAS</source><volume>95</volume><fpage>9214</fpage><lpage>9219</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.16.9214</pub-id><pub-id pub-id-type="pmid">9689060</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dar</surname><given-names>AC</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling</article-title><source>Annual Review of Biochemistry</source><volume>80</volume><fpage>769</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-090308-173656</pub-id><pub-id pub-id-type="pmid">21548788</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Roock</surname><given-names>W</given-names></name><name><surname>Jonker</surname><given-names>DJ</given-names></name><name><surname>Di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Lamba</surname><given-names>S</given-names></name><name><surname>Arena</surname><given-names>S</given-names></name><name><surname>Frattini</surname><given-names>M</given-names></name><name><surname>Piessevaux</surname><given-names>H</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>O’Callaghan</surname><given-names>CJ</given-names></name><name><surname>Khambata-Ford</surname><given-names>S</given-names></name><name><surname>Zalcberg</surname><given-names>JR</given-names></name><name><surname>Simes</surname><given-names>J</given-names></name><name><surname>Karapetis</surname><given-names>CS</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Tejpar</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab</article-title><source>JAMA</source><volume>304</volume><fpage>1812</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1535</pub-id><pub-id pub-id-type="pmid">20978259</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fröhlich</surname><given-names>F</given-names></name><name><surname>Gerosa</surname><given-names>L</given-names></name><name><surname>Muhlich</surname><given-names>J</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mechanistic model of MAPK signaling reveals How Allostery and rewiring contribute to Drug Resistance</article-title><source>Mol Syst Biol</source><volume>19</volume><elocation-id>e10988</elocation-id><pub-id pub-id-type="doi">10.1101/2022.02.17.480899</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujioka</surname><given-names>A</given-names></name><name><surname>Terai</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>RE</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Kuroda</surname><given-names>S</given-names></name><name><surname>Nishida</surname><given-names>E</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>8917</fpage><lpage>8926</lpage><pub-id pub-id-type="doi">10.1074/jbc.M509344200</pub-id><pub-id pub-id-type="pmid">16418172</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibney</surname><given-names>GT</given-names></name><name><surname>Messina</surname><given-names>JL</given-names></name><name><surname>Fedorenko</surname><given-names>IV</given-names></name><name><surname>Sondak</surname><given-names>VK</given-names></name><name><surname>Smalley</surname><given-names>KSM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma</article-title><source>Nature Reviews Clinical Oncology</source><volume>10</volume><fpage>390</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2013.83</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>TE</given-names></name><name><surname>Pargett</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>JM</given-names></name><name><surname>Teragawa</surname><given-names>CK</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><name><surname>Albeck</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway</article-title><source>Molecular Systems Biology</source><volume>16</volume><elocation-id>e9518</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20209518</pub-id><pub-id pub-id-type="pmid">33073539</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>L</given-names></name><name><surname>Mackey</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="1988">1988</year><source>From Clocks to Chaos: The Rhythms of Life.</source><publisher-name>Princeton University Press</publisher-name><pub-id pub-id-type="doi">10.1515/9780691221793</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutenkunst</surname><given-names>RN</given-names></name><name><surname>Waterfall</surname><given-names>JJ</given-names></name><name><surname>Casey</surname><given-names>FP</given-names></name><name><surname>Brown</surname><given-names>KS</given-names></name><name><surname>Myers</surname><given-names>CR</given-names></name><name><surname>Sethna</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Universally sloppy parameter sensitivities in systems biology models</article-title><source>PLOS Computational Biology</source><volume>3</volume><elocation-id>0030189</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0030189</pub-id><pub-id pub-id-type="pmid">17922568</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartsough</surname><given-names>EJ</given-names></name><name><surname>Kugel</surname><given-names>CH</given-names></name><name><surname>Vido</surname><given-names>MJ</given-names></name><name><surname>Berger</surname><given-names>AC</given-names></name><name><surname>Purwin</surname><given-names>TJ</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>MA</given-names></name><name><surname>Schiewer</surname><given-names>MJ</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Response and resistance to Paradox-Breaking BRAF inhibitor in Melanomas In Vivo and Ex Vivo</article-title><source>Molecular Cancer Therapeutics</source><volume>17</volume><fpage>84</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0705</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzivassiliou</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Yen</surname><given-names>I</given-names></name><name><surname>Brandhuber</surname><given-names>BJ</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name><name><surname>Alvarado</surname><given-names>R</given-names></name><name><surname>Ludlam</surname><given-names>MJC</given-names></name><name><surname>Stokoe</surname><given-names>D</given-names></name><name><surname>Gloor</surname><given-names>SL</given-names></name><name><surname>Vigers</surname><given-names>G</given-names></name><name><surname>Morales</surname><given-names>T</given-names></name><name><surname>Aliagas</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Sideris</surname><given-names>S</given-names></name><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Jaiswal</surname><given-names>BS</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Belvin</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</article-title><source>Nature</source><volume>464</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/nature08833</pub-id><pub-id pub-id-type="pmid">20130576</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidorn</surname><given-names>SJ</given-names></name><name><surname>Milagre</surname><given-names>C</given-names></name><name><surname>Whittaker</surname><given-names>S</given-names></name><name><surname>Nourry</surname><given-names>A</given-names></name><name><surname>Niculescu-Duvas</surname><given-names>I</given-names></name><name><surname>Dhomen</surname><given-names>N</given-names></name><name><surname>Hussain</surname><given-names>J</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Springer</surname><given-names>CJ</given-names></name><name><surname>Pritchard</surname><given-names>C</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</article-title><source>Cell</source><volume>140</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.12.040</pub-id><pub-id pub-id-type="pmid">20141835</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgkin</surname><given-names>AL</given-names></name><name><surname>Huxley</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="1952">1952</year><article-title>A quantitative description of membrane current and its application to conduction and excitation in nerve</article-title><source>The Journal of Physiology</source><volume>117</volume><fpage>500</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1952.sp004764</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holderfield</surname><given-names>M</given-names></name><name><surname>Merritt</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Wallroth</surname><given-names>M</given-names></name><name><surname>Tandeske</surname><given-names>L</given-names></name><name><surname>Zhai</surname><given-names>H</given-names></name><name><surname>Tellew</surname><given-names>J</given-names></name><name><surname>Hardy</surname><given-names>S</given-names></name><name><surname>Hekmat-Nejad</surname><given-names>M</given-names></name><name><surname>Stuart</surname><given-names>DD</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><name><surname>Nagel</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation</article-title><source>Cancer Cell</source><volume>23</volume><fpage>594</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.03.033</pub-id><pub-id pub-id-type="pmid">23680146</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Stites</surname><given-names>EC</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Germino</surname><given-names>EA</given-names></name><name><surname>Meharena</surname><given-names>HS</given-names></name><name><surname>Stork</surname><given-names>PJS</given-names></name><name><surname>Kornev</surname><given-names>AP</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Allosteric activation of functionally asymmetric RAF kinase dimers</article-title><source>Cell</source><volume>154</volume><fpage>1036</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.07.046</pub-id><pub-id pub-id-type="pmid">23993095</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huse</surname><given-names>M</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The conformational plasticity of protein kinases</article-title><source>Cell</source><volume>109</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00741-9</pub-id><pub-id pub-id-type="pmid">12015977</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Sahmi</surname><given-names>M</given-names></name><name><surname>David</surname><given-names>M</given-names></name><name><surname>Hilt</surname><given-names>C</given-names></name><name><surname>Hammell</surname><given-names>A</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1211</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01274-0</pub-id><pub-id pub-id-type="pmid">29084939</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karoulia</surname><given-names>Zoi</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Ahmed</surname><given-names>TA</given-names></name><name><surname>Xin</surname><given-names>Q</given-names></name><name><surname>Bollard</surname><given-names>J</given-names></name><name><surname>Krepler</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Fagin</surname><given-names>JA</given-names></name><name><surname>Lujambio</surname><given-names>A</given-names></name><name><surname>Gavathiotis</surname><given-names>E</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An integrated model of RAF inhibitor action predicts inhibitor activity against Oncogenic BRAF Signaling</article-title><source>Cancer Cell</source><volume>30</volume><fpage>501</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.08.008</pub-id><pub-id pub-id-type="pmid">27622340</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karoulia</surname><given-names>Z</given-names></name><name><surname>Gavathiotis</surname><given-names>E</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>New perspectives for targeting RAF kinase in human cancer</article-title><source>Nature Reviews. Cancer</source><volume>17</volume><fpage>676</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.79</pub-id><pub-id pub-id-type="pmid">28984291</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kholodenko</surname><given-names>BN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects</article-title><source>Cell Reports</source><volume>12</volume><fpage>1939</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.08.014</pub-id><pub-id pub-id-type="pmid">26344764</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>Y</given-names></name><name><surname>Niihori</surname><given-names>T</given-names></name><name><surname>Cavé</surname><given-names>H</given-names></name><name><surname>Verloes</surname><given-names>A</given-names></name><name><surname>Okamoto</surname><given-names>N</given-names></name><name><surname>Kawame</surname><given-names>H</given-names></name><name><surname>Fujiwara</surname><given-names>I</given-names></name><name><surname>Takada</surname><given-names>F</given-names></name><name><surname>Ohata</surname><given-names>T</given-names></name><name><surname>Sakazume</surname><given-names>S</given-names></name><name><surname>Ando</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>N</given-names></name><name><surname>Lapunzina</surname><given-names>P</given-names></name><name><surname>Meneses</surname><given-names>AG</given-names></name><name><surname>Gillessen-Kaesbach</surname><given-names>G</given-names></name><name><surname>Wieczorek</surname><given-names>D</given-names></name><name><surname>Kurosawa</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Ohashi</surname><given-names>H</given-names></name><name><surname>David</surname><given-names>A</given-names></name><name><surname>Philip</surname><given-names>N</given-names></name><name><surname>Guliyeva</surname><given-names>A</given-names></name><name><surname>Narumi</surname><given-names>Y</given-names></name><name><surname>Kure</surname><given-names>S</given-names></name><name><surname>Tsuchiya</surname><given-names>S</given-names></name><name><surname>Matsubara</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation</article-title><source>Human Mutation</source><volume>31</volume><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1002/humu.21187</pub-id><pub-id pub-id-type="pmid">20052757</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>Ognjenović</surname><given-names>J</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Karandur</surname><given-names>D</given-names></name><name><surname>Merk</surname><given-names>A</given-names></name><name><surname>Kulhanek</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>K</given-names></name><name><surname>Roose</surname><given-names>JP</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases</article-title><source>Science</source><volume>366</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1126/science.aay0543</pub-id><pub-id pub-id-type="pmid">31604311</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Thevakumaran</surname><given-names>N</given-names></name><name><surname>Gavory</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Padeganeh</surname><given-names>A</given-names></name><name><surname>Guiral</surname><given-names>S</given-names></name><name><surname>Duchaine</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>DYL</given-names></name><name><surname>Bouvier</surname><given-names>M</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</article-title><source>Nature Chemical Biology</source><volume>9</volume><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1257</pub-id><pub-id pub-id-type="pmid">23685672</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Thevakumaran</surname><given-names>N</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dimerization-induced allostery in protein kinase regulation</article-title><source>Trends in Biochemical Sciences</source><volume>39</volume><fpage>475</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2014.08.004</pub-id><pub-id pub-id-type="pmid">25220378</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of RAF protein kinases in ERK signalling</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>16</volume><fpage>281</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/nrm3979</pub-id><pub-id pub-id-type="pmid">25907612</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Autoinhibition with transcriptional delay: a simple mechanism for the zebrafish somitogenesis oscillator</article-title><source>Current Biology</source><volume>13</volume><fpage>1398</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1016/s0960-9822(03)00534-7</pub-id><pub-id pub-id-type="pmid">12932323</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liau</surname><given-names>NPD</given-names></name><name><surname>Wendorff</surname><given-names>TJ</given-names></name><name><surname>Quinn</surname><given-names>JG</given-names></name><name><surname>Steffek</surname><given-names>M</given-names></name><name><surname>Phung</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Irudayanathan</surname><given-names>FJ</given-names></name><name><surname>Izadi</surname><given-names>S</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name><name><surname>Hymowitz</surname><given-names>SG</given-names></name><name><surname>Sudhamsu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1038/s41594-019-0365-0</pub-id><pub-id pub-id-type="pmid">31988522</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez Fiesco</surname><given-names>JA</given-names></name><name><surname>Durrant</surname><given-names>DE</given-names></name><name><surname>Morrison</surname><given-names>DK</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>486</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28084-3</pub-id><pub-id pub-id-type="pmid">35078985</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFall</surname><given-names>T</given-names></name><name><surname>Diedrich</surname><given-names>JK</given-names></name><name><surname>Mengistu</surname><given-names>M</given-names></name><name><surname>Littlechild</surname><given-names>SL</given-names></name><name><surname>Paskvan</surname><given-names>KV</given-names></name><name><surname>Sisk-Hackworth</surname><given-names>L</given-names></name><name><surname>Moresco</surname><given-names>JJ</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name><name><surname>Stites</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A systems mechanism for KRAS mutant allele-specific responses to targeted therapy</article-title><source>Science Signaling</source><volume>12</volume><elocation-id>eaaw8288</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaw8288</pub-id><pub-id pub-id-type="pmid">31551296</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFall</surname><given-names>T</given-names></name><name><surname>Schomburg</surname><given-names>NK</given-names></name><name><surname>Rossman</surname><given-names>KL</given-names></name><name><surname>Stites</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors</article-title><source>Cell Communication and Signaling</source><volume>18</volume><elocation-id>179</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-020-00645-3</pub-id><pub-id pub-id-type="pmid">33153459</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFall</surname><given-names>T</given-names></name><name><surname>Stites</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach</article-title><source>Cell Reports</source><volume>37</volume><elocation-id>110096</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110096</pub-id><pub-id pub-id-type="pmid">34910921</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>MM</given-names></name><name><surname>Ritt</surname><given-names>DA</given-names></name><name><surname>Morrison</surname><given-names>DK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling</article-title><source>Current Biology</source><volume>21</volume><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2011.02.033</pub-id><pub-id pub-id-type="pmid">21458265</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Mendiratta</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Raf-PA</data-title><version designator="swh:1:rev:9e7f8d2bd9adb44de1ad9f990db189a2cb411097">swh:1:rev:9e7f8d2bd9adb44de1ad9f990db189a2cb411097</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:9b4e5859272128cc2858c0fc5bfaad7709829dda;origin=https://github.com/GMendiratta/RAF-PA;visit=swh:1:snp:3f3993ec885bd0ce695a643c6710bece8ab9bf4a;anchor=swh:1:rev:9e7f8d2bd9adb44de1ad9f990db189a2cb411097">https://archive.softwareheritage.org/swh:1:dir:9b4e5859272128cc2858c0fc5bfaad7709829dda;origin=https://github.com/GMendiratta/RAF-PA;visit=swh:1:snp:3f3993ec885bd0ce695a643c6710bece8ab9bf4a;anchor=swh:1:rev:9e7f8d2bd9adb44de1ad9f990db189a2cb411097</ext-link></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>L</given-names></name><name><surname>Menten</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1913">1913</year><article-title>Die kinetik der invertinwirkung</article-title><source>Biochemische Zeitschrift</source><volume>49</volume><elocation-id>352</elocation-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Arita</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>S</given-names></name><name><surname>Donelan</surname><given-names>J</given-names></name><name><surname>Chouitar</surname><given-names>J</given-names></name><name><surname>Carideo</surname><given-names>E</given-names></name><name><surname>Galvin</surname><given-names>K</given-names></name><name><surname>Okaniwa</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma</article-title><source>Cancer Research</source><volume>73</volume><fpage>7043</fpage><lpage>7055</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1825</pub-id><pub-id pub-id-type="pmid">24121489</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1962">1962</year><article-title>A modification of the Hodgkin--Huxley equations applicable to Purkinje fibre action and pace-maker potentials</article-title><source>The Journal of Physiology</source><volume>160</volume><fpage>317</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1962.sp006849</pub-id><pub-id pub-id-type="pmid">14480151</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandit</surname><given-names>B</given-names></name><name><surname>Sarkozy</surname><given-names>A</given-names></name><name><surname>Pennacchio</surname><given-names>LA</given-names></name><name><surname>Carta</surname><given-names>C</given-names></name><name><surname>Oishi</surname><given-names>K</given-names></name><name><surname>Martinelli</surname><given-names>S</given-names></name><name><surname>Pogna</surname><given-names>EA</given-names></name><name><surname>Schackwitz</surname><given-names>W</given-names></name><name><surname>Ustaszewska</surname><given-names>A</given-names></name><name><surname>Landstrom</surname><given-names>A</given-names></name><name><surname>Bos</surname><given-names>JM</given-names></name><name><surname>Ommen</surname><given-names>SR</given-names></name><name><surname>Esposito</surname><given-names>G</given-names></name><name><surname>Lepri</surname><given-names>F</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Mundel</surname><given-names>P</given-names></name><name><surname>López Siguero</surname><given-names>JP</given-names></name><name><surname>Tenconi</surname><given-names>R</given-names></name><name><surname>Selicorni</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>C</given-names></name><name><surname>Mazzanti</surname><given-names>L</given-names></name><name><surname>Torrente</surname><given-names>I</given-names></name><name><surname>Marino</surname><given-names>B</given-names></name><name><surname>Digilio</surname><given-names>MC</given-names></name><name><surname>Zampino</surname><given-names>G</given-names></name><name><surname>Ackerman</surname><given-names>MJ</given-names></name><name><surname>Dallapiccola</surname><given-names>B</given-names></name><name><surname>Tartaglia</surname><given-names>M</given-names></name><name><surname>Gelb</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy</article-title><source>Nature Genetics</source><volume>39</volume><fpage>1007</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/ng2073</pub-id><pub-id pub-id-type="pmid">17603483</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Rawson</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>B-W</given-names></name><name><surname>Ficarro</surname><given-names>SB</given-names></name><name><surname>Pino</surname><given-names>GG-D</given-names></name><name><surname>Sharif</surname><given-names>H</given-names></name><name><surname>Marto</surname><given-names>JA</given-names></name><name><surname>Jeon</surname><given-names>H</given-names></name><name><surname>Eck</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes</article-title><source>Nature</source><volume>575</volume><fpage>545</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1660-y</pub-id><pub-id pub-id-type="pmid">31581174</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>SB</given-names></name><name><surname>Henry</surname><given-names>JR</given-names></name><name><surname>Kaufman</surname><given-names>MD</given-names></name><name><surname>Lu</surname><given-names>WP</given-names></name><name><surname>Smith</surname><given-names>BD</given-names></name><name><surname>Vogeti</surname><given-names>S</given-names></name><name><surname>Rutkoski</surname><given-names>TJ</given-names></name><name><surname>Wise</surname><given-names>S</given-names></name><name><surname>Chun</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Van Horn</surname><given-names>RD</given-names></name><name><surname>Yin</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Webster</surname><given-names>Y</given-names></name><name><surname>Buchanan</surname><given-names>S</given-names></name><name><surname>Mochalkin</surname><given-names>I</given-names></name><name><surname>Huber</surname><given-names>L</given-names></name><name><surname>Kays</surname><given-names>L</given-names></name><name><surname>Donoho</surname><given-names>GP</given-names></name><name><surname>Walgren</surname><given-names>J</given-names></name><name><surname>McCann</surname><given-names>D</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Conti</surname><given-names>I</given-names></name><name><surname>Plowman</surname><given-names>GD</given-names></name><name><surname>Starling</surname><given-names>JJ</given-names></name><name><surname>Flynn</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers</article-title><source>Cancer Cell</source><volume>28</volume><fpage>384</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.08.002</pub-id><pub-id pub-id-type="pmid">26343583</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</article-title><source>Nature</source><volume>464</volume><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/nature08902</pub-id><pub-id pub-id-type="pmid">20179705</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Persaud</surname><given-names>Y</given-names></name><name><surname>Janakiraman</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Ng</surname><given-names>C</given-names></name><name><surname>Moriceau</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Atefi</surname><given-names>M</given-names></name><name><surname>Titz</surname><given-names>B</given-names></name><name><surname>Gabay</surname><given-names>MT</given-names></name><name><surname>Salton</surname><given-names>M</given-names></name><name><surname>Dahlman</surname><given-names>KB</given-names></name><name><surname>Tadi</surname><given-names>M</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Kelley</surname><given-names>MC</given-names></name><name><surname>Misteli</surname><given-names>T</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</article-title><source>Nature</source><volume>480</volume><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1038/nature10662</pub-id><pub-id pub-id-type="pmid">22113612</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rukhlenko</surname><given-names>OS</given-names></name><name><surname>Khorsand</surname><given-names>F</given-names></name><name><surname>Krstic</surname><given-names>A</given-names></name><name><surname>Rozanc</surname><given-names>J</given-names></name><name><surname>Alexopoulos</surname><given-names>LG</given-names></name><name><surname>Rauch</surname><given-names>N</given-names></name><name><surname>Erickson</surname><given-names>KE</given-names></name><name><surname>Hlavacek</surname><given-names>WS</given-names></name><name><surname>Posner</surname><given-names>RG</given-names></name><name><surname>Gómez-Coca</surname><given-names>S</given-names></name><name><surname>Rosta</surname><given-names>E</given-names></name><name><surname>Fitzgibbon</surname><given-names>C</given-names></name><name><surname>Matallanas</surname><given-names>D</given-names></name><name><surname>Rauch</surname><given-names>J</given-names></name><name><surname>Kolch</surname><given-names>W</given-names></name><name><surname>Kholodenko</surname><given-names>BN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dissecting RAF Inhibitor resistance by structure-based modeling reveals ways to overcome Oncogenic RAS Signaling</article-title><source>Cell Systems</source><volume>7</volume><fpage>161</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2018.06.002</pub-id><pub-id pub-id-type="pmid">30007540</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadaie</surname><given-names>W</given-names></name><name><surname>Harada</surname><given-names>Y</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantitative in vivo fluorescence cross-correlation analyses highlight the importance of competitive effects in the regulation of protein-protein interactions</article-title><source>Molecular and Cellular Biology</source><volume>34</volume><fpage>3272</fpage><lpage>3290</lpage><pub-id pub-id-type="doi">10.1128/MCB.00087-14</pub-id><pub-id pub-id-type="pmid">24958104</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skoulidis</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>BT</given-names></name><name><surname>Dy</surname><given-names>GK</given-names></name><name><surname>Price</surname><given-names>TJ</given-names></name><name><surname>Falchook</surname><given-names>GS</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Italiano</surname><given-names>A</given-names></name><name><surname>Schuler</surname><given-names>M</given-names></name><name><surname>Borghaei</surname><given-names>H</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sotorasib for Lung Cancers with KRAS p G12C Mutation</article-title><source>The New England Journal of Medicine</source><volume>384</volume><fpage>2371</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2103695</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stites</surname><given-names>EC</given-names></name><name><surname>Trampont</surname><given-names>PC</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Ravichandran</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Network analysis of oncogenic Ras activation in cancer</article-title><source>Science</source><volume>318</volume><fpage>463</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1126/science.1144642</pub-id><pub-id pub-id-type="pmid">17947584</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stites</surname><given-names>EC</given-names></name><name><surname>Trampont</surname><given-names>PC</given-names></name><name><surname>Haney</surname><given-names>LB</given-names></name><name><surname>Walk</surname><given-names>SF</given-names></name><name><surname>Ravichandran</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cooperation between Noncanonical Ras Network Mutations</article-title><source>Cell Reports</source><volume>10</volume><elocation-id>840</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.048</pub-id><pub-id pub-id-type="pmid">30849858</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Viros</surname><given-names>A</given-names></name><name><surname>Milagre</surname><given-names>C</given-names></name><name><surname>Trunzer</surname><given-names>K</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Spleiss</surname><given-names>O</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Koya</surname><given-names>RC</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Hayward</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Hilton</surname><given-names>H</given-names></name><name><surname>Hang</surname><given-names>JS</given-names></name><name><surname>Noe</surname><given-names>J</given-names></name><name><surname>Lambros</surname><given-names>M</given-names></name><name><surname>Geyer</surname><given-names>F</given-names></name><name><surname>Dhomen</surname><given-names>N</given-names></name><name><surname>Niculescu-Duvaz</surname><given-names>I</given-names></name><name><surname>Zambon</surname><given-names>A</given-names></name><name><surname>Niculescu-Duvaz</surname><given-names>D</given-names></name><name><surname>Preece</surname><given-names>N</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Otte</surname><given-names>NJ</given-names></name><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>Kee</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Habets</surname><given-names>G</given-names></name><name><surname>Burton</surname><given-names>EA</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Kockx</surname><given-names>M</given-names></name><name><surname>Andries</surname><given-names>L</given-names></name><name><surname>Lestini</surname><given-names>B</given-names></name><name><surname>Nolop</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Joe</surname><given-names>AK</given-names></name><name><surname>Troy</surname><given-names>JL</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Springer</surname><given-names>CJ</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1105358</pub-id><pub-id pub-id-type="pmid">22256804</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thevakumaran</surname><given-names>N</given-names></name><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Critton</surname><given-names>DA</given-names></name><name><surname>Tebben</surname><given-names>A</given-names></name><name><surname>Marinier</surname><given-names>A</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>22</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2924</pub-id><pub-id pub-id-type="pmid">25437913</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>A</given-names></name><name><surname>Ehrenreiter</surname><given-names>K</given-names></name><name><surname>Aschenbrenner</surname><given-names>B</given-names></name><name><surname>Kocieniewski</surname><given-names>P</given-names></name><name><surname>Kochanczyk</surname><given-names>M</given-names></name><name><surname>Lipniacki</surname><given-names>T</given-names></name><name><surname>Baccarini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα</article-title><source>Science Signaling</source><volume>10</volume><elocation-id>eaai8482</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aai8482</pub-id><pub-id pub-id-type="pmid">28270557</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellbrock</surname><given-names>C</given-names></name><name><surname>Karasarides</surname><given-names>M</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The RAF proteins take centre stage</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>5</volume><fpage>875</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/nrm1498</pub-id><pub-id pub-id-type="pmid">15520807</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilker</surname><given-names>E</given-names></name><name><surname>Yaffe</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>14-3-3 Proteins--a focus on cancer and human disease</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>37</volume><fpage>633</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2004.04.015</pub-id><pub-id pub-id-type="pmid">15350836</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wofsy</surname><given-names>C</given-names></name><name><surname>Goldstein</surname><given-names>B</given-names></name><name><surname>Lund</surname><given-names>K</given-names></name><name><surname>Wiley</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Implications of epidermal growth factor (EGF) induced EGF receptor aggregation</article-title><source>Biophysical Journal</source><volume>63</volume><fpage>98</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(92)81572-2</pub-id><pub-id pub-id-type="pmid">1420877</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>WH</given-names></name><name><surname>Yap</surname><given-names>J</given-names></name><name><surname>Chia</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>14276</fpage><lpage>14284</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.004597</pub-id><pub-id pub-id-type="pmid">30030377</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Spevak</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Burton</surname><given-names>EA</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Habets</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Ewing</surname><given-names>T</given-names></name><name><surname>Matusow</surname><given-names>B</given-names></name><name><surname>Tsang</surname><given-names>G</given-names></name><name><surname>Marimuthu</surname><given-names>A</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Fong</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Womack</surname><given-names>P</given-names></name><name><surname>Nespi</surname><given-names>M</given-names></name><name><surname>Shellooe</surname><given-names>R</given-names></name><name><surname>Carias</surname><given-names>H</given-names></name><name><surname>Powell</surname><given-names>B</given-names></name><name><surname>Light</surname><given-names>E</given-names></name><name><surname>Sanftner</surname><given-names>L</given-names></name><name><surname>Walters</surname><given-names>J</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Visor</surname><given-names>G</given-names></name><name><surname>Rezaei</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>PS</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name><name><surname>Ibrahim</surname><given-names>PN</given-names></name><name><surname>Hirth</surname><given-names>P</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RAF inhibitors that evade paradoxical MAPK pathway activation</article-title><source>Nature</source><volume>526</volume><fpage>583</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1038/nature14982</pub-id><pub-id pub-id-type="pmid">26466569</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>B-Raf autoinhibition in the presence and absence of 14-3-3</article-title><source>Structure</source><volume>29</volume><fpage>768</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/j.str.2021.02.005</pub-id><pub-id pub-id-type="pmid">33711246</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Supplementary theory</title><p>The theory of ordinary differential equations (ODEs) was developed alongside calculus by Newton, Leibniz, Bernoulli, Riccati, and others in the 17th century. Nonlinear differential equations are extensively used in research including to model biological systems of neural signaling, protein interactions, and cardiac potentials; however, these are rife with singularities and numerical instabilities. Through this long history, differential equations that can be fully solved and are applicable to real-world conditions are quite rare. Hence, scientifically relevant, analytically accessible solutions are of considerable value to both progress of applied mathematics and quantitative sciences. In this work, we show such solutions under equilibrium conditions for a set of ODE models that describe the dimerization and drug binding of RAF proto-oncoproteins. Our work includes a series of mathematical models involving RAF dimerization, drug binding, RAF CA, and the interactions that affect these component processes. Each of these models is based on evidence from multiple sources in the literature that support the modeled RAF activation cycle and drug interactions. The value of such analytically solved models is both in their generalizability and in their global predictions. For example, in the first section, we will show that it is not possible to generate PA in a system where RAF monomer can dimerize and where drug binds equivalently well to monomeric and dimeric RAF proteins. This statement is derived independent of any parameter values that may be used – this is an ‘analytic’ result. Other examples in biological literature of similarly powerful analytic studies include Michaelis–Menten enzyme kinetics (<xref ref-type="bibr" rid="bib39">Michaelis and Menten, 1913</xref>), negative feedback-based oscillatory circuits (<xref ref-type="bibr" rid="bib12">Glass and Mackey, 1988</xref>; <xref ref-type="bibr" rid="bib31">Lewis, 2003</xref>), and the Hodgkin–Huxley model (<xref ref-type="bibr" rid="bib18">Hodgkin and Huxley, 1952</xref>; <xref ref-type="bibr" rid="bib41">Noble, 1962</xref>).</p><p>The molecular interaction rates for RAF activation and drug binding all occur on a time scale of protein–protein and protein–ligand interactions (<xref ref-type="bibr" rid="bib9">Fujioka et al., 2006</xref>; <xref ref-type="bibr" rid="bib11">Gillies et al., 2020</xref>), which are orders of magnitude smaller than the time scales of paradoxical activation and proliferation phenotypes associated with MAPK pathway activation (<xref ref-type="bibr" rid="bib16">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Heidorn et al., 2010</xref>) or the time scale of clinical impact (<xref ref-type="bibr" rid="bib10">Gibney et al., 2013</xref>). We therefore focus on steady-state levels of the different states in which RAF can exist within our models. At equilibrium, we derive expressions for the relative abundance of the RAF within its different monomeric and dimeric states. We perform algebraic manipulations and derive analytic solutions that we reproduce using Mathematica software. We solve the equilibrium state numerically where it is instructive as visual aid to the analytical results or where analytic results cannot be obtained globally.</p><p>Within Appendix 1, we first describe a model of RAF dimerization and drug binding, followed by a model of autoinhibition without dimerization, and then a model that combines these two components. A numerical illustration of the mathematical model used that displays the drug dose-dependent response of the different states of RAF is included as <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>, with narrative text in the main article under the section ‘ Paradoxical activation reflects a shifting balance of signaling complexes.’ The NC and DP mechanisms utilized in unified mechanisms model have been discussed in detail in the literature (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>). We show the resulting expressions in the unified model in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> (and use these in <xref ref-type="fig" rid="fig3">Figure 3</xref> plots and fits) and the derivations thereof are included in Mathematica code present in the included supplementary code files. We provide a numerical illustration of the unified model that displays the drug dose-dependent response of the different states of RAF included as the last section of Appendix 1.</p></sec><sec sec-type="appendix" id="s9"><title>The promotion of RAF dimerization by a drug does not induce PA by itself</title><p>We begin by constructing a model of kinase activation to dispel a possible misunderstanding of the behavior possible through RAF dimerization and drug binding alone. In the mechanism that we model (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>), a kinase exists in the competent/non-autoinhibited form (denoted by capital <italic>A</italic>) where it may dimerize (<italic>AA</italic>) and bind with the drug in the monomeric (<italic>Ad</italic>) or dimer form (<italic>AAd,AdAd</italic>). This model resembles a similar, older model of EGFR activation and dimerization (<xref ref-type="bibr" rid="bib57">Wofsy et al., 1992</xref>). We can assign an equilibrium constant to each of the reactions that is equal to the ratio of reactants to the products:<disp-formula id="equ3"><mml:math id="m3"><mml:mi>K</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Therefore, the process of drug binding has an equilibrium rate constant <inline-formula><mml:math id="inf30"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>:<disp-formula id="equ4"><mml:math id="m4"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>The process of non-autoinhibited kinase dimerization corresponds to the equilibrium rate constant <inline-formula><mml:math id="inf31"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>:<disp-formula id="equ5"><mml:math id="m5"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>We derive closed-form, analytic steady-state solutions relating the above rate constants with protein and drug concentrations using the principle of detailed balance (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>; <xref ref-type="bibr" rid="bib57">Wofsy et al., 1992</xref>). At equilibrium, the principle of detailed balance or microscopic reversibility ensures that all cyclical processes have a zero change in Gibbs free energy. Free energy with a constant temperature, pressure, and pH is proportional to the logarithm of the equilibrium rate constant. Hence, corresponding to the network described in <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>, we obtain the following relations:<disp-formula id="equ6"><mml:math id="m6"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>and<disp-formula id="equ7"><mml:math id="m7"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Since there are two binding locations for the drug in a dimer (<inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>), the reaction is twice as likely, and the dissociation constant is halved <inline-formula><mml:math id="inf33"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula>. From the detailed balance equation, we calculate that <inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, hence connecting drug binding to the dimerization process via dynamical equilibrium relationships. In this first, simple, model, we assume that the drug does not induce any changes in the kinase conformation and therefore the dimerization of drug-bound kinase proceeds at the same rate as unbound kinase, <inline-formula><mml:math id="inf35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> . We can now calculate the last unknown rate, <inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. Thereby, only two rate constants determine the equilibrium state of this system.</p><p>To calculate the steady-state or equilibrium relationships, we begin with reactions that lead from a RAF protomer to a fully drug-bound RAF dimer:<disp-formula id="equ8"><mml:math id="m8"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>The following expressions correspond to the rate constants for the above reactions:<disp-formula id="equ9"><mml:math id="m9"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>​</mml:mi><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>​</mml:mi><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>​</mml:mi><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>The total amount of drug and kinase is obtained by combining all states that are assumed unchanged over the short reaction times involved in the binding and unbinding molecular reactions, and are defined as below:<disp-formula id="equ10"><mml:math id="m10"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>​</mml:mi><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>Replacing the equilibrium concentrations into the expression for total kinase concentration, we first solve for the total number of unbound RAF protomers:<disp-formula id="equ11"><mml:math id="m11"><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:msqrt><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf37"><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf38"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. The total quantity of active protomers is a sum of the protomers in the kinase dimers and the dimers bound to one drug, (<inline-formula><mml:math id="inf39"><mml:mn>2</mml:mn><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula>). Substituting the equilibrium concentrations, the concentration of active kinase at equilibrium is obtained:<disp-formula id="equ12"><mml:math id="m12"><mml:mn>2</mml:mn><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Utilizing the previously calculated equilibrium concentration of non-autoinhibited monomer kinase, we can reduce the above expression to a function of the dimensionless ratios <inline-formula><mml:math id="inf40"><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf41"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>:<disp-formula id="equ13"><mml:math id="m13"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:msqrt></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>8</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>It is clear that the above expression for active kinase protomers is a monotonically reducing function of the unbound drug concentration since that variable only occurs in the denominator. The second component required to analytically establish the absence of paradoxical activation in this model is to prove that the unbound drug is monotonically and proportionally related to total drug concentration. We do this by substituting the equilibrium relations, which provides the total drug amount:<disp-formula id="equ14"><mml:math id="m14"><mml:mrow><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>A</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>Next, we substitute the equilibrium kinase monomer concentration [<italic>A</italic>] in the above expression to solve for equilibrium unbound drug concentration [<italic>d</italic>].<disp-formula id="equ15"><mml:math id="m15"><mml:mo>[</mml:mo><mml:mi>d</mml:mi><mml:mo>]</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>ζ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msqrt><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>ζ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:msqrt></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf42"><mml:msub><mml:mrow><mml:mi>ζ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mo>-</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. Therefore, the relationship between total and unbound drug concentrations is monotonic and directly related.</p><p>We therefore show that active RAF is an inverse function of drug concentration. <italic>PA is not possible while considering only simple dimerization and drug binding processes of RAF protein</italic>. This point may not have been sufficiently stressed in the literature, leading to confusion about the added dimers are induced by the drug causing PA by themselves. These new, partly drug-bound, dimers will never create additional RAF signaling protomers unless there was more to the RAF activation processes than dimerization and drug binding. For example, DP, where the affinity for RAF dimerization is higher if one (or both) RAF protomers is bound to a RAF inhibitor, has previously been demonstrated as an addition to the above modeled mechanism that could result in a PA response to RAF inhibitor (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>).</p></sec><sec sec-type="appendix" id="s10"><title>Autoinhibited proteins active as monomers will not display PA from drug-induced stabilization of the non-autoinhibited form alone</title><p>Extensive research has searched for explanations of PA that go beyond DP. These mechanisms include drug NC, RAS oligomerization, downstream negative feedback release, and more. One of these mechanisms, based on RAF CA, is particularly interesting because it does not involve any new, drug-induced, structural conformations of the RAF protein. With a simple extension to our modeled network, we identify the conditions under which this phenomenon successfully provides a mechanism for PA in response to inhibition of dimerizing kinases.</p><p>We first model drug-mediated stabilization of the active form of a conformation autoinhibition-regulated kinase for a kinase that does not dimerize and is fully active as a monomer. To study this, we create a model where the kinase may autoinhibit (denoted by <italic>‘a</italic>’) to become reversibly inactive and where a drug will only bind the non-autoinhibited form (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>). The following equilibria contribute to this network:<disp-formula id="equ16"><mml:math id="m16"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>a</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>with corresponding equilibrium dissociation constants defined as follows:<disp-formula id="equ17"><mml:math id="m17"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>The total drug and kinase amounts are calculated as below:<disp-formula id="equ18"><mml:math id="m18"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>​</mml:mi><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>We solve the above four equations for the total non-autoinhibited protomers ([<italic>A</italic>]) as a function of total concentrations and equilibrium dissociation constants:<disp-formula id="equ19"><mml:math id="m19"><mml:mi>A</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msqrt><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>4</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:msqrt><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf43"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:mo>-</mml:mo><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula>. The function monotonically reduces to zero as the total drug increases to a large value. Therefore, <italic>a kinase that can signal downstream as a monomer does not show anomalous activation upon drug inhibition even though there is a reservoir available to shift the equilibrium to activated kinase</italic>.</p></sec><sec sec-type="appendix" id="s11"><title>The combination of conformational autoinhibition and stabilization of the active form by a drug can generate PA</title><p>Conformational changes of the RAF monomer contribute significantly to the regulation of RAF kinase activity (<xref ref-type="bibr" rid="bib30">Lavoie and Therrien, 2015</xref>; <xref ref-type="bibr" rid="bib55">Wellbrock et al., 2004</xref>). In the ‘autoinhibited’ form, associations between its N-terminus and its kinase domain maintain RAF in an inactive form that does not dimerize (<xref ref-type="bibr" rid="bib5">Cutler et al., 1998</xref>; <xref ref-type="bibr" rid="bib30">Lavoie and Therrien, 2015</xref>). In the ‘non-autoinhibited’ form, the kinase domain is no longer occluded, and other regulatory mechanisms contribute to full RAF kinase activation, such as kinase domain conformational changes and dimerization (<xref ref-type="bibr" rid="bib28">Lavoie et al., 2013</xref>). Recent experimental work reports that RAF inhibitors tend to promote a net transition to the non-autoinhibited conformation that binds to RAS-GTP (<xref ref-type="bibr" rid="bib22">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Karoulia et al., 2017</xref>). It has previously been suggested that this biasing to the non-autoinhibited state may contribute to PA (<xref ref-type="bibr" rid="bib22">Jin et al., 2017</xref>).</p><p>To study the conditions under which the stabilization of RAF in its non-autoinhibited state by RAF inhibitors may be sufficient to generate PA, we create a mathematical model that includes RAF CA, RAF dimerization, and RAF inhibitor (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>). The model allows RAF to adopt two different conformations: one is autoinhibited and can neither dimerize nor bind drug, and the other is non-autoinhibited and can bind drug and/or dimerize (<xref ref-type="bibr" rid="bib28">Lavoie et al., 2013</xref>). Drug-bound RAF is assumed to only be able to transition back to an autoinhibited state after any bound drug has dissociated. Within the model, wild-type RAF is implicitly assumed to be activated by RAS-GTP as binding to RAS-GTP is an essential step to wild-type RAF activation (<xref ref-type="bibr" rid="bib30">Lavoie and Therrien, 2015</xref>). We define active RAF as the RAF protomers that are not bound to a drug and are part of a RAF dimer. The following expressions identify the different interactions included in this network:<disp-formula id="equ20"><mml:math id="m20"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mi>a</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd><mml:mtd><mml:mo>⇋</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>The processes in this model include autoinhibition, which, for simplicity, is modeled as a first-order transition from autoinhibited state <inline-formula><mml:math id="inf44"><mml:mi>a</mml:mi></mml:math></inline-formula> to non-autoinhibited state <inline-formula><mml:math id="inf45"><mml:mi>A</mml:mi></mml:math></inline-formula> with a rate constant <inline-formula><mml:math id="inf46"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>:<disp-formula id="equ21"><mml:math id="m21"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mo>→</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>The equilibrium equations defined in the previous section apply in the base model with the addition of the CA dynamical equilibrium represented in above equation. Over the reaction periods, we assume that the total RAF and drug concentrations remain unchanged, leading to the conservation equations below:<disp-formula id="equ22"><mml:math id="m22"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>A</mml:mi><mml:mi>d</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>Following the analysis described in the first section, we solve the RAF conservation equation to find the concentration of unbound non-autoinhibited RAF:<disp-formula id="equ23"><mml:math id="m23"><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:msqrt><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>8</mml:mn><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt><mml:mi> </mml:mi><mml:mo>-</mml:mo><mml:mi> </mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>Note that there is no explicit dependence on the drug binding rate <inline-formula><mml:math id="inf47"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and only on the ratio of the free drug concentration to <inline-formula><mml:math id="inf48"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> appears explicitly (<italic>d</italic><sub>rel</sub> = [<italic>d</italic>]/<italic>K</italic><sub><italic>d</italic></sub>). Similarly, dimerization rate constant <inline-formula><mml:math id="inf49"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> can be combined with the total amount of RAF protein <inline-formula><mml:math id="inf50"><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . This reduces the model from four varying parameters to two effective parameters, which govern all predictions. The total active kinase is the sum of drug-unbound RAF protomers in a drug-unbound RAF dimer and partly drug-bound RAF dimer.<disp-formula id="equ24"><mml:math id="m24"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>Substituting the above equation and the equilibrium conditions, we obtain the active RAF proportion shown in the first column of <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. This function is not monotonic, and the behavior can be defined by evaluating the zeroes of the derivatives of the function. The first derivative of the function representing active RAF protein simplifies to the following expression:<disp-formula id="equ25"><mml:math id="m25"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msqrt><mml:mi>E</mml:mi><mml:msup><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mo>​</mml:mo><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:msqrt><mml:mi>E</mml:mi><mml:msup><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:msqrt></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mn>3</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msqrt><mml:mi>E</mml:mi><mml:msup><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:msqrt><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf51"><mml:mi>E</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf52"><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:mn>8</mml:mn><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . Maximal paradoxical activation, if it exists, occurs when the first derivative of active RAF relative to the drug concentration is zero. We calculate the values of <inline-formula><mml:math id="inf53"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, which satisfy this condition and find that only one solution can potentially be real and positive:<disp-formula id="equ26"><mml:math id="m26"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mo> </mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mi>F</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msqrt><mml:mfenced separators="|"><mml:mrow><mml:mn>6</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:msqrt><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></disp-formula></p><p>To additionally establish that this point of inflection is a maximum, we need to establish conditions under which the second derivative of the active RAF equation relative to <inline-formula><mml:math id="inf54"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is negative. At the drug concentration in the above equation, the second derivative of active RAF simplifies to the following expression:<disp-formula id="equ27"><mml:math id="m27"><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mi>d</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>6</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:msqrt></mml:mrow><mml:mrow><mml:mn>324</mml:mn><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msubsup><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>6</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:msqrt><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>6</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></disp-formula></p><p>This function is negative definite as long as the parameters are all positive. The latter is a given since the parameters are either concentrations (non-negative) or ratios of concentrations (equilibrium constants). The drug will show paradoxical activation via the suggested autoinhibition mechanism when the value of <inline-formula><mml:math id="inf55"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is positive. We find that the maximum fold change occurs at a positive drug concentration only when the following condition is true to derive the necessary and sufficient condition for PA within this sub-model:<disp-formula id="equ28"><mml:math id="m28"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd/><mml:mtd><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>3</mml:mn><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>As the concentration ratio <inline-formula><mml:math id="inf56"><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> may not be smaller than 0, the right-hand expression is always positive. Therefore, the condition that the autoinhibition equilibrium should favor the inactive RAF kinase naturally arises from the above expression (i.e., <inline-formula><mml:math id="inf57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>). <italic>In other words, PA does not always happen when CA is present</italic>. It is also clear from the same expression that a model that does not show autoinhibition (<inline-formula><mml:math id="inf58"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>) or a model where there are no dimers (<inline-formula><mml:math id="inf59"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>→</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>:</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>→</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>) will not produce PA. <italic>Therefore, we demonstrate analytically that the presence of both CA and stabilization of the active form by RAF inhibitors is sufficient to create PA for a wide range of system parameters</italic>.</p><p>Next, we identify the predictions of this model for the baseline RAF signaling, defined as active RAF in the absence of the drug. The expression for baseline signaling in the basic model is shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. This expression is positive definite and monotonic as a function of E3, where <inline-formula><mml:math id="inf60"><mml:mi>E</mml:mi><mml:mn>3</mml:mn><mml:mo>=</mml:mo><mml:mn>8</mml:mn><mml:mo>×</mml:mo><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. This can be observed by taking the first derivative relative to E3, which reduces to the following positive definite function:<disp-formula id="equ29"><mml:math id="m29"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mo>_</mml:mo><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msqrt><mml:mi>E</mml:mi><mml:mn>3</mml:mn><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:msqrt><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:msup><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msqrt><mml:mi>E</mml:mi><mml:mn>3</mml:mn><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:msqrt></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Therefore, baseline signaling monotonically increases as a function of RAF concentration and reduces as a function of equilibrium constant <inline-formula><mml:math id="inf61"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and equilibrium dissociation constant <inline-formula><mml:math id="inf62"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>.</p><p>Moreover, expression for the maximum paradoxical activation can be calculated by substituting the corresponding value of drug concentration into the expression for active kinase concentration:<disp-formula id="equ30"><mml:math id="m30"><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msqrt><mml:mn>6</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:msqrt><mml:mo>+</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>6</mml:mn><mml:msqrt><mml:mn>6</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:msqrt><mml:mo>-</mml:mo><mml:mn>9</mml:mn></mml:mrow></mml:mfenced><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>27</mml:mn><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Note that in this mechanism the maximal kinase activity is a simple inverse function of <inline-formula><mml:math id="inf63"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . Since the minimum value of <inline-formula><mml:math id="inf64"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> to produce PA limits to 1 from above, the maximum possible PA for a kinase is a function of <inline-formula><mml:math id="inf65"><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> only. This is also because we have modeled the autoinhibitory mechanism in the simplest possible, first-order approximation that represents the phenomena itself but may not encompass the detailed dynamics such as that modeled in the following sections. The kinase activity in the absence of the drug is shown in the following expression:<disp-formula id="equ31"><mml:math id="m31"><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>→</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mo>-</mml:mo><mml:msqrt><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:msqrt><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:msup><mml:mrow><mml:mi>​</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>The maximal fold change (FC) in activity can therefore be calculated:<disp-formula id="equ32"><mml:math id="m32"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mi>M</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mi>F</mml:mi><mml:mi>C</mml:mi></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>→</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>8</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:msqrt><mml:mn>6</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:msqrt><mml:mo>+</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>6</mml:mn><mml:msqrt><mml:mn>6</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:msqrt><mml:mo>-</mml:mo><mml:mn>9</mml:mn></mml:mrow></mml:mfenced><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>27</mml:mn><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mo>-</mml:mo><mml:msqrt><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>8</mml:mn><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:msqrt><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:msup><mml:mrow><mml:mi>​</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>When the conditions of PA are satisfied, the fold change monotonically increases as a function of the autoinhibition equilibrium constant and reduces as a function of the RAF concentration to dimerization dissociation constant ratio. Both of these facts can be derived upon evaluating the first derivative of the fold change function above and applying the constraint relationship for PA existence, which results in a positive definite derivative relative to <inline-formula><mml:math id="inf66"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and a negative definite derivative relative to <inline-formula><mml:math id="inf67"><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. The implication of the former is that when the autoinhibition equilibrium favors the inactive state, the fold change relative to baseline (drug-free) condition is enhanced. Further, when the dimerization rate of RAF increases (i.e., dissociation constant <inline-formula><mml:math id="inf68"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> reduces), the corresponding increase in <inline-formula><mml:math id="inf69"><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> leads to a reduced fold change in RAF activity in response to the drug, relative to the control.</p></sec><sec sec-type="appendix" id="s12"><title>The relationship between unbound drug and total drug</title><p>We note here that the expressions characterizing the PA phenomenon thus far are done as a function of the free-drug concentration. This is to keep the expressions relatively simple. The total drug available in a cell also includes the drug concentration bound to RAF, including both monomeric and dimeric states of RAF. Our conclusions become final predictions of the model once we can show that unbound/free drug and the total drug concentrations are directly and monotonically related.</p><p>The relationship between total drug available (DTOT) and the unbound (free) drug (<italic>d</italic>) can be calculated by substituting the equilibrium conditions:<disp-formula id="equ33"><mml:math id="m33"><mml:mtable columnalign="right"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mfenced separators="|"><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>D</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>where the unbound kinase (<italic>A</italic>) is a function of free drug (<italic>d</italic>). After splitting this function into three additive terms, we substitute the expression for [<italic>A</italic>] and show that the derivative relative to unbound drug for each term is non-negative. We do not show the explicit expression for these derivatives here and refer to the Mathematica notebook provided as <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. We note that these derivatives are positive definite for all positive values of the parameters in the model. Therefore, we obtain that the total drug quantity is a monotonic increasing function of the quantity of unbound drug (<xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref>). The monotonicity of this function implies that our conclusions for paradoxical activation follow through as a function of total drug as well. However, the nonlinear relationship implies that the map between drug IC-50 values and the free-drug amount is directly related but also nonlinear. This is significant while comparing IC-50 values predicted by a modeling framework with experimental results. When fitting our RAF activity functions to experimental data, we work with the total drug concentration.</p></sec><sec sec-type="appendix" id="s13"><title>Numerical model illustrations of three mechanisms of PA: NC, DP, and CA</title><p><xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref> shows the mechanisms of drug potentiation of RAF dimerization (DP, blue line), NC (red dotted line), CA (green dashed line), and the unified model with all three mechanisms (unified, black dashed line). We illustrate each of the states of RAF (i–vi) for each of the sub-models, in a manner similar to what is shown in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>, but now extended to include these additional models. The CA and DP mechanisms show distinct features in active RAF states. The DP model shows a rapid activation of RAF in response to a dimerization-inducing drug (blue, solid line) and then a rapid reduction of signaling. In contrast, the PA peak occurs at higher drug concentrations for the CA model, and the CA model also has a much wider tail of the distribution (green, dashed line). The NC model (red, dotted curves) also shows some increase of the partly active RAF dimer at low drug concentrations. However, this mechanism alone will not generate PA as the total abundance of active RAF protomers within RAF dimers will always be less than the levels obtained in the absence of drug. This point can also be shown as a parameter-independent, analytic feature of the NC model (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) and is in agreement with prior in silico modeling of the NC mechanism (<xref ref-type="bibr" rid="bib25">Kholodenko, 2015</xref>). We show in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref> that in the presence of other mechanisms that induce PA, the NC model can modulate the dose–response curve to activate RAF at higher concentrations of the drug. The nature of their contributions remains quite distinct across the DP, NC, and CA models even as they combine to create more complex dose–response.</p><p>All of the mechanisms are combined into a unified model (black, dashed), which incorporates the unique features of each of the sub-models. The curves in <xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref> identify the differences within the models and also show the synergistic combination of the mechanisms. We also note the analytic expressions for each of the models in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> are linearly independent, and therefore cannot be converted into each other by any simple translation or scaling transformation of any of the variables. The hypothesis that we could completely characterize these parameters using normalized data from signaling experiments arose from this insight into the analytic and numerical activation curves. These fits may be performed in the future for other cell lines, primary cells, mouse models, or any system of interest where such characterization may aid in drug development and precision therapy identification. The clear distinguishability of different mechanisms using fitting is an emergent feature due to the nonlinearities between how the models combine. The distinguishability is a rare feature in multiparameter models because of degeneracies that are common in multiparameter models. An example of a degeneracy in our model system involves the abundance of RAF and the dimerization equilibrium constant; these terms are difficult to isolate from each other in our fits. The coarse-grained data signaling data in our fits is much improved with narrower and more robust parameter regions predicted when the RAF concentration and dimerization rates are fixed to values based on the literature.</p><p>Finally, while NC and drug-induced increases in dimerization are behaviors that can be tuned between RAF inhibitors, we highlight that CA is a feature that spans all RAF inhibitors. This means that this process and the secondary events that potentiate this process are important factors to consider in the development of any RAF inhibitor.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Schematic of base RAF dimerization and drug binding model that does not include conformational autoinhibition, negative cooperativity, or drug-induced dimerization.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-app1-fig1-v2.tif"/></fig><fig id="app1fig2" position="float"><label>Appendix 1—figure 2.</label><caption><title>Schematic of conformational autoinhibition and inhibitor binding, where inhibitor can only bind the non-autoinhibited form of the target protein.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-app1-fig2-v2.tif"/></fig><fig id="app1fig3" position="float"><label>Appendix 1—figure 3.</label><caption><title>Schematic of the base model extended to include conformational autoinhibition.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-app1-fig3-v2.tif"/></fig><fig id="app1fig4" position="float"><label>Appendix 1—figure 4.</label><caption><title>Plot of the relationship between unbound drug and total drug.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-app1-fig4-v2.tif"/></fig><fig id="app1fig5" position="float"><label>Appendix 1—figure 5.</label><caption><title>Visualization of how paradoxical activation (PA) arises when conformational autoinhibition with inhibitor stabilization, dimer potentiation, and/or negative cooperativity are present.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82739-app1-fig5-v2.tif"/></fig></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82739.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jura</surname><given-names>Natalia</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/849489" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/849489"/></front-stub><body><p>This important study uses mathematical modeling to demonstrate that conformational autoinhibition of the RAF kinase is an important feature of its paradoxical activation by pharmacological inhibitors. The provided theoretical analysis is highly compelling and increases the mechanistic understanding of how regulation by the N-terminal regulatory domains of RAF contributes to the paradoxical effect of the inhibitors. This article is poised to be of interest to biochemists, cell biologists, and cancer biologists, ultimately paving the way for improved RAF therapeutics.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82739.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Jura</surname><given-names>Natalia</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Albeck</surname><given-names>John G</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>University of California, Davis</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/849489">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/849489v2.full">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;RAF conformational autoinhibition and 14-3-3 proteins promote paradoxical activation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Volker Dötsch as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: John G Albeck (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>All reviewers are in agreement that the main strengths of the manuscript include a theoretical demonstration that conformational autoinhibition is an important feature of Raf kinase paradoxical activation in response to Raf-targeted therapies and the finding that paradoxical activation can arise in the absence of negative cooperativity and the dimerizing effect of Raf kinase inhibitors. There is consensus that these findings provide a significant advancement in the understanding of the Raf paradoxical activation phenomenon. Reviewers were also in agreement about the weaknesses of this study. One of them is lack of the experimental data that directly test whether paradoxical activation is reduced when conformational autoinhibition is removed. Another weakness stems from the concern that the 14-3-3-dependent effects described in the paper might not be relevant at the physiological 14-3-3 levels due to 14-3-3 abundance in a cell. Lack of the experimental data that directly test these effects is another weakness. Thus, the recommendation for publishing this work at <italic>eLife</italic> is pending a major revision, which could take two paths:</p><p>1) The manuscript in its current form needs to be supported by stronger direct experimental evidence. The reviewers acknowledge that experimental validation of conformational autoinhibition as a contributing factor to the paradoxical activation might be difficult and agree that the theoretical model provided is sufficient. However, all reviewers agree that the 14-3-3 regulation should be supported by more direct experimental evidence that eliminates the ambiguity of interpretation that stems from conditions of 14-3-3 overexpression. A recommendation for such an experiment is provided by Reviewer #1.</p><p>2) Acknowledging that experimental work might be out of the scope of the PI's lab expertise, another proposed revision path is to remove the section that describes the 14-3-3-based regulation from the current manuscript. All reviewers agree that this would make a more focused paper that would highlight its most impactful findings and eliminate concerns about how 14-3-3 levels in a cell can be regulated to functionally contribute to the proposed effects.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. The reported roles of conformational autoinhibition and 14-3-3 binding in PA of RAF are very exciting findings of this study but remain to be experimentally validated. The phosphorylation site on RAF, which recruits 14-3-3 stabilizing RAF autoinhibition is known, and mutating this site should destabilize the autoinhibited state of RAF. This study would be greatly enhanced by the analysis of such, or functionally analogous mutants that disrupt RAF inactive state, to investigate the contribution of conformational autoinhibition of RAF to PA.</p><p>2. To evaluate the contribution of 14-3-3 to PA of RAF, authors investigate the roles of 14-3-3 in conformational autoinhibition stabilization (CAS) or dimer stabilization (DS) models (Figure 4C). By doing so they found DS failed to potentiate PA. The authors do not elaborate much on this, but since DS is an established mechanism to potentiate PA, why do the authors think DS does not play a role in this context? Could the authors use RAF and/or 14-3-3 mutations to decouple the CAS and DS effect of 14-3-3?</p><p>3. Figure 1. title sound overreaching as the figure does not show an analysis of PA with mathematical models.</p><p>4. Figure 1A. graph axes should indicate which way RAF inhibitor concentration and RAF activity increase for X and Y axes, respectively.</p><p>5. Figure 4C typing error, CAS+MS should be CAS+DS.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Overall my recommendations mainly focus on clarifying how some of the model results are presented and explained, as the current representation isn't fully adequate to see how the fits are working.</p><p>1. It should be considered whether a direct test of the role of conformational autoinhibition can be performed using Raf proteins that lack the autoinhibitory domain, which has been used for some time. Understandably, such an experiment could be difficult to execute, as it would likely require the other native forms of Raf to be deleted. Alternatively, it may be the case that data in the literature using such mutants could provide insight. If neither of these is possible, it would be helpful to at least discuss how such an experimental test could be set up and how its outcome could support or contradict the model.</p><p>2. It is somewhat confusing what is going on with the fitted parameter sets in Figure 3. The text refers to 28 or 30 parameter sets, and it is not clear what these parameters are or which two parameters are omitted in the 28. How do the 28 parameters relate to the 27 drug-specific parameters in Table S1? Also, what do the different iterations of the same symbol represent in Figure 3C and Figure S2C? Overall, in addition to clarifying these ambiguities, it would be helpful to present the complete parameter sets more comprehensively, such as in a heatmap, in addition to the f vs. Kd plot.</p><p>3. The discussion of the fits of the different model variants makes the statement that &quot;Our analysis also suggests that all three mechanisms make important contributions to the overall PA behavior in a drug-specific manner&quot;, but the drug-specific aspect of these fits is not detailed in any of the figures. This should be made more clear by showing the fits for specific types of inhibitors for each of the models, to support this statement.</p><p>4. The &quot;clustering&quot; of different inhibitor types in the f vs. Kd plot is a somewhat loose interpretation given the sparseness of the points within the space and their relative distances. It seems like it would be more accurate to say that inhibitors of the same type occupy common regions of parameter space. Also, given that g values also differ over at least 10-fold, it would be helpful to include a visualization that shows how this factor distributes as well.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>First, a comment on the scope of my review. I approach the paper with a deep appreciation for the power of mathematical modeling and an abiding interest in RAF regulation and the PA phenomenon, but I am not a mathematician. Thus, I leave review of this aspect of the paper to other referees and simply assume that the authors have gotten the math right – that they have properly implemented the models as they've described them.</p><p>A couple of things you might consider:</p><p>1. At a fixed 14-3-3 concentration, I would think that the effect of 14-3-3 binding could be subsumed with adjustments to Ka and Kdim. If this is correct, it would be helpful to point it out and if not, to explain why not.</p><p>2. You nicely show how PA varies with Ka in the model in Fig. 2. It would be helpful to also see how it varies with Kd and Kdim. Are there regimes of inhibitor affinity in which is it more/less pronounced?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82739.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>All reviewers are in agreement that the main strengths of the manuscript include a theoretical demonstration that conformational autoinhibition is an important feature of Raf kinase paradoxical activation in response to Raf-targeted therapies and the finding that paradoxical activation can arise in the absence of negative cooperativity and the dimerizing effect of Raf kinase inhibitors. There is consensus that these findings provide a significant advancement in the understanding of the Raf paradoxical activation phenomenon. Reviewers were also in agreement about the weaknesses of this study. One of them is lack of the experimental data that directly test whether paradoxical activation is reduced when conformational autoinhibition is removed. Another weakness stems from the concern that the 14-3-3-dependent effects described in the paper might not be relevant at the physiological 14-3-3 levels due to 14-3-3 abundance in a cell. Lack of the experimental data that directly test these effects is another weakness. Thus, the recommendation for publishing this work at eLife is pending a major revision, which could take two paths:</p><p>1) The manuscript in its current form needs to be supported by stronger direct experimental evidence. The reviewers acknowledge that experimental validation of conformational autoinhibition as a contributing factor to the paradoxical activation might be difficult and agree that the theoretical model provided is sufficient. However, all reviewers agree that the 14-3-3 regulation should be supported by more direct experimental evidence that eliminates the ambiguity of interpretation that stems from conditions of 14-3-3 overexpression. A recommendation for such an experiment is provided by Reviewer #1.</p><p>2) Acknowledging that experimental work might be out of the scope of the PI's lab expertise, another proposed revision path is to remove the section that describes the 14-3-3-based regulation from the current manuscript. All reviewers agree that this would make a more focused paper that would highlight its most impactful findings and eliminate concerns about how 14-3-3 levels in a cell can be regulated to functionally contribute to the proposed effects.</p></disp-quote><p>We thank the reviewers and the editor for the reviews and for the options. We are pleased that there is agreement about the significant value of recognizing the conformational autoinhibition mechanism as an essential part of understanding paradoxical activation.</p><p>We are resubmitting under option #2, the proposed option to focus on the theoretical results and to eliminate the section on 14-3-3. We are very pleased with the agreement about the value of the theoretical work. Our revised manuscript is focused, as the reviewers stated it would be, and we have made changes and additions to address the reviewer’s requests. The requests were all very logical and these additions further strengthen the manuscript. We are very pleased with how this has turned out, and we hope the reviewers and editors are also happy with the revision.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. The reported roles of conformational autoinhibition and 14-3-3 binding in PA of RAF are very exciting findings of this study but remain to be experimentally validated. The phosphorylation site on RAF, which recruits 14-3-3 stabilizing RAF autoinhibition is known, and mutating this site should destabilize the autoinhibited state of RAF. This study would be greatly enhanced by the analysis of such, or functionally analogous mutants that disrupt RAF inactive state, to investigate the contribution of conformational autoinhibition of RAF to PA.</p></disp-quote><p>Although we have removed the 14-3-3 section and are not doing experiments in the present study, we agree that this would be an excellent approach for experimental testing of the theoretical ideas presented in the manuscript. We have extended our discussion to discuss this phosphorylation event and mutations that disrupt it, and how they may be useful for future experimental work. Specifically, we have updated the manuscript’s discussion to state:</p><p>“Experimental testing of model predictions is an important next step. One possible approach for experimentally investigating the role of conformational autoinhibition on PA would involve RAF proteins that are defective in conformational autoinhibition. Of note, there are some RAF mutants in Noonan syndrome that are believed to be activating due to impaired regulation of conformational autoinhibition. For example, stabilization of the autoinhibited form of CRAF involves the phosphorylation of serine at residue 259 followed by 14-3-3 binding to the phosphorylated serine. The S257L, S259F, P261A, and N262K CRAF mutations are impaired at binding to 14-3-3 and have severely impaired phosphorylation of serine 259 (Kobayashi <italic>et al.,</italic> 2010; Pandit <italic>et al.,</italic> 2007). Alternatively, truncation mutants lacking the autoinhibitory domain could be used. In such experiments, comparisons of RAF inhibitor dose responses between cells expressing one such mutant against control cells expressing the wild-type equivalent RAF protein would reveal whether there were changes in PA fold-change and PA range (as defined in Figure 2). We would expect to see reduced PA fold-change and reduced PA range for the conformational autoinhibition impaired mutants. We anticipate PA range would be the more useful observable because nonlinearities in downstream signaling (including possible saturation of readouts like ERK phosphorylation) may make measurements of fold-change less useful. As PA range is determined by when the signal passes back through the baseline level after the increase induced by a RAF inhibitor, it should be less impacted by nonlinear signal processing downstream from RAF. Whether the experiment utilizes Noonan syndrome RAF1 mutants or truncated RAF mutants, the presence of endogenous, wild-type BRAF, ARAF, and CRAF may make it difficult to observe differences in PA due to an introduced mutant, so such experiments may need to be performed in cells where the three endogenous RAF genes are knocked out or silenced.”</p><disp-quote content-type="editor-comment"><p>2. To evaluate the contribution of 14-3-3 to PA of RAF, authors investigate the roles of 14-3-3 in conformational autoinhibition stabilization (CAS) or dimer stabilization (DS) models (Figure 4C). By doing so they found DS failed to potentiate PA. The authors do not elaborate much on this, but since DS is an established mechanism to potentiate PA, why do the authors think DS does not play a role in this context? Could the authors use RAF and/or 14-3-3 mutations to decouple the CAS and DS effect of 14-3-3?</p></disp-quote><p>In the revision, we have cut this section per Option 2 of focusing on conformational autoinhibition. In our future work, we plan to pursue experiments that will use mutants to focus on just one role of 14-3-3 on RAF, in line with the suggestion.</p><disp-quote content-type="editor-comment"><p>3. Figure 1. title sound overreaching as the figure does not show an analysis of PA with mathematical models.</p></disp-quote><p>We have updated the title of Figure 1, thank you for catching this.</p><disp-quote content-type="editor-comment"><p>4. Figure 1A. graph axes should indicate which way RAF inhibitor concentration and RAF activity increase for X and Y axes, respectively.</p></disp-quote><p>We have updated our schematic in Figure 1A to indicate which direction has increasing RAF inhibitor and increasing RAF activity (x and y axes, respectively) and noted this in our updated figure legend. Thank you for this suggestion.</p><disp-quote content-type="editor-comment"><p>5. Figure 4C typing error, CAS+MS should be CAS+DS.</p></disp-quote><p>Thank you for catching this. Although we have now removed the 14-3-3 section that included this, we have made the correction so that we will not make the same mistake in our continuing studies. Thank you.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Overall my recommendations mainly focus on clarifying how some of the model results are presented and explained, as the current representation isn't fully adequate to see how the fits are working.</p><p>1. It should be considered whether a direct test of the role of conformational autoinhibition can be performed using Raf proteins that lack the autoinhibitory domain, which has been used for some time. Understandably, such an experiment could be difficult to execute, as it would likely require the other native forms of Raf to be deleted. Alternatively, it may be the case that data in the literature using such mutants could provide insight. If neither of these is possible, it would be helpful to at least discuss how such an experimental test could be set up and how its outcome could support or contradict the model.</p></disp-quote><p>We have added a section in the discussion that elaborates on some experimental testing. It is copy-and-pasted in the response to Reviewer #1. This new section mentions the potential for truncation mutants without the autoinhibitory domain, or for Noonan syndrome RAF1 mutants with impaired autoinhbition (due to impaired 14-3-3 stabilization of the closed form) to serve as possible vehicles to test the role of CA. The challenge of the endogenous, native forms is also mentioned. We also discuss what we expect (reduced PA with these mutants) and which read-out (PA range) should be the better measurement and why. Thank you for this suggestion. We think this addition should make the theoretical results of greater interest to experimental biologists, and we appreciate the suggestion. Thank you.</p><disp-quote content-type="editor-comment"><p>2. It is somewhat confusing what is going on with the fitted parameter sets in Figure 3. The text refers to 28 or 30 parameter sets, and it is not clear what these parameters are or which two parameters are omitted in the 28. How do the 28 parameters relate to the 27 drug-specific parameters in Table S1?</p></disp-quote><p>Thank you for requesting us to clarify this section. We agree that this the previous version was confusing and should have been more clearly communicated. We have revised and updated the section where these parameters are introduced to be more clear and more thorough. Specifically, the new text reads:</p><p>“We set values for two key parameters, RAF abundance and RAF dimerization equilibrium constant based on estimates and do not fit them. A table listing the best-fit parameters of each of the sub-models, are indicated in Supplementary File 1. Of note, we have one global parameter (the autoinhibition equilibrium constant) and twenty-seven drug-specific parameters. Our twenty eight total parameter estimates yield a model that matches the experimental data well (Figure 3B). Details of our approach for identifying model parameters are provided in the methods, and our code is in the supplement. We obtain similar quality overall fits if we do not pre-specify the RAF abundance and the RAF dimerization constant and add these two parameters to the other twenty eight parameters and then perform the same parameter estimation procedure (Figure 3 —figure supplement 1C-E). We observed that some parameters could be constrained to a narrow region through this procedure, while other parameters could vary widely and still match the same data (Figure 3 —figure supplement 2,3).”</p><disp-quote content-type="editor-comment"><p>Also, what do the different iterations of the same symbol represent in Figure 3C and Figure S2C?</p></disp-quote><p>We have updated the text to clarify this in multiple places. First, within the main text, where the parameter fits are first mentioned we added the following sentence:</p><p>“We developed a computational process for obtaining sets of parameters that fit our model to published experimental data (Karoulia et al., 2016). Our approach finds multiple parameter sets for the same drug that are within 10% of the error for the parameter set with the least error. Within the text, we also have the following sentence to communicate the value of having multiple, similar quality, fits.”</p><p>We also plot alternative parameter estimates that are within 10% error of the considered parameter set with the least error, and this helps demonstrate the robustness of this observation.</p><p>Within the figure legend, we have added this sentence:</p><p>“For each drug, we show all obtained best fit parameter sets that were within 10% of best fit metric.”</p><disp-quote content-type="editor-comment"><p>Overall, in addition to clarifying these ambiguities, it would be helpful to present the complete parameter sets more comprehensively, such as in a heatmap, in addition to the f vs. Kd plot.</p></disp-quote><p>We have made three changes to more thoroughly communicate the parameter sets.</p><p>– We have added a supplementary figure (Figure 3 —figure supplement 3) that shows the values and the ranges for the 28 parameters (3 parameters x 9 drugs, and one global KA parameters), and we show these for all variants of the model (full model, and versions where one or more of the three different mechanisms of the model are systematically excluded).</p><p>– We have added a supplementary figure (Figure 3 —figure supplement 2) that shows the best fits for the model and different submodels analyzed in Figure 3.</p><p>– We have extended and improved our supplementary table to present the best fit parameters for all sub-models. (Supplementary File 1)</p><disp-quote content-type="editor-comment"><p>3. The discussion of the fits of the different model variants makes the statement that &quot;Our analysis also suggests that all three mechanisms make important contributions to the overall PA behavior in a drug-specific manner&quot;, but the drug-specific aspect of these fits is not detailed in any of the figures. This should be made more clear by showing the fits for specific types of inhibitors for each of the models, to support this statement.</p></disp-quote><p>We have elaborated and expanded this section. The new text now reads:</p><p>“Altogether, we believe that our analysis provides strong support for conformational autoinhibition being a critical factor to PA. Our sub-model analysis suggests that both conformational autoinhibition and dimer potentiation are necessary for the mathematical model to reproduce the experimental data with the smallest degree of error. Even though the negative cooperativity term ‘g’ was not strongly constrained, and even though it had the smallest impact on the ability of the model to fit the experimental data, the model fits consistently had values of g that were much larger than one (Table S1) which is consistent with negative cooperativity. Thus, our analysis suggests that all three processes contribute to the overall PA phenomenon.”</p><disp-quote content-type="editor-comment"><p>4. The &quot;clustering&quot; of different inhibitor types in the f vs. Kd plot is a somewhat loose interpretation given the sparseness of the points within the space and their relative distances. It seems like it would be more accurate to say that inhibitors of the same type occupy common regions of parameter space.</p></disp-quote><p>We have made the following changes:</p><p>– Eliminated the use of the term “clustering”.</p><p>– Rephrased that section to read:</p><p>“Intriguingly, when we considered the collection of best-fit parameters we found the different RAF inhibitors appeared to separate in a manner reflective of their known identity as Type I, Type I.5, and Type II inhibitors (Figure 3C, Supplementary File 1).”</p><disp-quote content-type="editor-comment"><p>Also, given that g values also differ over at least 10-fold, it would be helpful to include a visualization that shows how this factor distributes as well.</p></disp-quote><p>We have added a new supplementary figure (Figure 3 —figure supplement 3), which includes box-and-whisker plots that show the range of parameter values for g for each of the 9 drugs fit to, as well as f, Kd, and KA values. Thank you for your review and the helpful suggestions to improve the manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>First, a comment on the scope of my review. I approach the paper with a deep appreciation for the power of mathematical modeling and an abiding interest in RAF regulation and the PA phenomenon, but I am not a mathematician. Thus, I leave review of this aspect of the paper to other referees and simply assume that the authors have gotten the math right – that they have properly implemented the models as they've described them.</p><p>A couple of things you might consider:</p><p>1. At a fixed 14-3-3 concentration, I would think that the effect of 14-3-3 binding could be subsumed with adjustments to Ka and Kdim. If this is correct, it would be helpful to point it out and if not, to explain why not.</p></disp-quote><p>We have added the following sentences to the manuscript:</p><p>“Intuitively, stabilization of RAF conformational autoinhibition by itself would result in a stronger PA and could be approximated as an increase in the K<sub>A</sub> term within our model. RAF stabilization of RAF dimers could be approximated as in increase in the K<sub>dim</sub> term within our model. Thank you for this suggestion.”</p><disp-quote content-type="editor-comment"><p>2. You nicely show how PA varies with Ka in the model in Fig. 2. It would be helpful to also see how it varies with Kd and Kdim. Are there regimes of inhibitor affinity in which is it more/less pronounced?</p></disp-quote><p>We have added new supplementary figure (Figure 2 —figure supplement 1) that show this information.</p></body></sub-article></article>